

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advancements in the management of... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-476/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-476" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advancements in the management of retinoblastoma and uveal melanoma" />
    
            <meta name="og:title" content="F1000Research Article: Recent advancements in the management of retinoblastoma and uveal melanoma.">
            <meta name="og:description" content="Read the latest article version by Amy C Schefler, Ryan S Kim, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="12907">
            <meta name="article-id" content="11941">
            <meta name="dc.title" content="Recent advancements in the management of retinoblastoma and uveal melanoma">
            <meta name="dc.description" content="Retinoblastoma and uveal melanoma are the most common intraocular malignancies observed in pediatric and adult populations, respectively. For retinoblastoma, intra-arterial chemotherapy has dramatically improved treatment outcomes and eye salvage rates compared with traditional salvage rates of systemic chemotherapy and external beam radiation therapy. Intravitreal injections of chemotherapy have also demonstrated excellent efficacy for vitreous seeds. Uveal melanoma, on the other hand, is treated predominantly with iodine-125 plaque brachytherapy or with proton beam therapy. Major strides in uveal melanoma genomics have been made since the early 2000s, allowing ocular oncologists to better understand the metastatic risks of the tumor on the basis of specific genetic signatures. Loss-of-function mutations of the BAP1 gene are associated with the highest metastatic risk, whereas gain-of-function mutations of SF3B1 and EIF1AX often confer a better prognosis. Expression of a cancer-testis antigen called PRAME (preferentially expressed antigen in melanoma) has been shown to increase metastatic risks in both low-risk and high-risk melanomas. New therapeutic approaches, including molecular therapies and nanoparticle phototherapy, are currently being investigated as alternative treatment modalities for uveal melanoma.">
            <meta name="dc.subject" content="retinoblastoma, uveal melanoma, ocular tumors">
            <meta name="dc.creator" content="Schefler, Amy C">
            <meta name="dc.creator" content="Kim, Ryan S">
            <meta name="dc.date" content="2018/04/18">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.11941.1">
            <meta name="dc.source" content="F1000Research 2018 7:476">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="retinoblastoma">
            <meta name="prism.keyword" content="uveal melanoma">
            <meta name="prism.keyword" content="ocular tumors">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/04/18">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="476">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.11941.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-476">
            <meta name="citation_title" content="Recent advancements in the management of retinoblastoma and uveal melanoma">
            <meta name="citation_abstract" content="Retinoblastoma and uveal melanoma are the most common intraocular malignancies observed in pediatric and adult populations, respectively. For retinoblastoma, intra-arterial chemotherapy has dramatically improved treatment outcomes and eye salvage rates compared with traditional salvage rates of systemic chemotherapy and external beam radiation therapy. Intravitreal injections of chemotherapy have also demonstrated excellent efficacy for vitreous seeds. Uveal melanoma, on the other hand, is treated predominantly with iodine-125 plaque brachytherapy or with proton beam therapy. Major strides in uveal melanoma genomics have been made since the early 2000s, allowing ocular oncologists to better understand the metastatic risks of the tumor on the basis of specific genetic signatures. Loss-of-function mutations of the BAP1 gene are associated with the highest metastatic risk, whereas gain-of-function mutations of SF3B1 and EIF1AX often confer a better prognosis. Expression of a cancer-testis antigen called PRAME (preferentially expressed antigen in melanoma) has been shown to increase metastatic risks in both low-risk and high-risk melanomas. New therapeutic approaches, including molecular therapies and nanoparticle phototherapy, are currently being investigated as alternative treatment modalities for uveal melanoma.">
            <meta name="citation_description" content="Retinoblastoma and uveal melanoma are the most common intraocular malignancies observed in pediatric and adult populations, respectively. For retinoblastoma, intra-arterial chemotherapy has dramatically improved treatment outcomes and eye salvage rates compared with traditional salvage rates of systemic chemotherapy and external beam radiation therapy. Intravitreal injections of chemotherapy have also demonstrated excellent efficacy for vitreous seeds. Uveal melanoma, on the other hand, is treated predominantly with iodine-125 plaque brachytherapy or with proton beam therapy. Major strides in uveal melanoma genomics have been made since the early 2000s, allowing ocular oncologists to better understand the metastatic risks of the tumor on the basis of specific genetic signatures. Loss-of-function mutations of the BAP1 gene are associated with the highest metastatic risk, whereas gain-of-function mutations of SF3B1 and EIF1AX often confer a better prognosis. Expression of a cancer-testis antigen called PRAME (preferentially expressed antigen in melanoma) has been shown to increase metastatic risks in both low-risk and high-risk melanomas. New therapeutic approaches, including molecular therapies and nanoparticle phototherapy, are currently being investigated as alternative treatment modalities for uveal melanoma.">
            <meta name="citation_keywords" content="retinoblastoma, uveal melanoma, ocular tumors">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Amy C Schefler">
            <meta name="citation_author_institution" content="Retina Consultants of Houston, Houston, TX, 77030, USA">
            <meta name="citation_author_institution" content="Blanton Eye Institute, Houston Methodist Hospital, Houston, TX, 77030, USA">
            <meta name="citation_author" content="Ryan S Kim">
            <meta name="citation_author_institution" content="Retina Consultants of Houston, Houston, TX, 77030, USA">
            <meta name="citation_author_institution" content="McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, 77030, USA">
            <meta name="citation_publication_date" content="2018/04/18">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="476">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.11941.1">
            <meta name="citation_firstpage" content="476">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-476/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-476.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=12907 /> <input type=hidden id=articleId name=articleId value=11941 /> <input type=hidden id=xmlUrl value="/articles/7-476/v1/xml"/> <input type=hidden id=xmlFileName value="-7-476-v1.xml"> <input type=hidden id=article_uuid value=25b3bcb9-73e7-4de1-899f-a51009853953 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advancements in the management of retinoblastoma and uveal melanoma"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.11941.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.11941.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-476"
  },
  "headline": "Recent advancements in the management of retinoblastoma and uveal melanoma",
  "datePublished": "2018-04-18T14:28:15",
  "dateModified": "2018-04-18T14:28:15",
  "author": [
    {
      "@type": "Person",
      "name": "Amy C Schefler"
    },    {
      "@type": "Person",
      "name": "Ryan S Kim"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Retinoblastoma and uveal melanoma are the most common intraocular malignancies observed in pediatric and adult populations, respectively. For retinoblastoma, intra-arterial chemotherapy has dramatically improved treatment outcomes and eye salvage rates compared with traditional salvage rates of systemic chemotherapy and external beam radiation therapy. Intravitreal injections of chemotherapy have also demonstrated excellent efficacy for vitreous seeds. Uveal melanoma, on the other hand, is treated predominantly with iodine-125 plaque brachytherapy or with proton beam therapy. Major strides in uveal melanoma genomics have been made since the early 2000s, allowing ocular oncologists to better understand the metastatic risks of the tumor on the basis of specific genetic signatures. Loss-of-function mutations of the BAP1 gene are associated with the highest metastatic risk, whereas gain-of-function mutations of SF3B1 and EIF1AX often confer a better prognosis. Expression of a cancer-testis antigen called PRAME (preferentially expressed antigen in melanoma) has been shown to increase metastatic risks in both low-risk and high-risk melanomas. New therapeutic approaches, including molecular therapies and nanoparticle phototherapy, are currently being investigated as alternative treatment modalities for uveal melanoma."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-476",
            "name": "Recent advancements in the management of retinoblastoma and uveal..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advancements in the management of retinoblastoma and uveal... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=12907 data-id=11941 data-downloads="" data-views="" data-scholar="10.12688/f1000research.11941.1" data-recommended="" data-doi="10.12688/f1000research.11941.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-476/v1/pdf?article_uuid=25b3bcb9-73e7-4de1-899f-a51009853953" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-11941-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-11941-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-11941-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Schefler AC and Kim RS. Recent advancements in the management of retinoblastoma and uveal melanoma [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):476 (<a class=new-orange href="https://doi.org/10.12688/f1000research.11941.1" target=_blank>https://doi.org/10.12688/f1000research.11941.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-11941-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=11941 id=track-article-signin-11941 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/11941?target=/articles/7-476">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=12907 /> <input name=articleId type=hidden value=11941 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advancements in the management of retinoblastoma and uveal melanoma</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:acsmd@houstonretina.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Amy C Schefler</span></a><sup>1,2</sup>,&nbsp;</span><span class="">Ryan S Kim<sup>1,3</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:acsmd@houstonretina.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Amy C Schefler</span></a><sup>1,2</sup>,&nbsp;</span><span class="">Ryan S Kim<sup>1,3</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 18 Apr 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.11941.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Retina Consultants of Houston, Houston, TX, 77030, USA<br/> <sup>2</sup> Blanton Eye Institute, Houston Methodist Hospital, Houston, TX, 77030, USA<br/> <sup>3</sup> McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, 77030, USA<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=33421-32996></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=33423-32997></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Retinoblastoma and uveal melanoma are the most common intraocular malignancies observed in pediatric and adult populations, respectively. For retinoblastoma, intra-arterial chemotherapy has dramatically improved treatment outcomes and eye salvage rates compared with traditional salvage rates of systemic chemotherapy and external beam radiation therapy. Intravitreal injections of chemotherapy have also demonstrated excellent efficacy for vitreous seeds. Uveal melanoma, on the other hand, is treated predominantly with iodine-125 plaque brachytherapy or with proton beam therapy. Major strides in uveal melanoma genomics have been made since the early 2000s, allowing ocular oncologists to better understand the metastatic risks of the tumor on the basis of specific genetic signatures. Loss-of-function mutations of the <i>BAP1</i> gene are associated with the highest metastatic risk, whereas gain-of-function mutations of <i>SF3B1 </i>and <i>EIF1AX</i> often confer a better prognosis. Expression of a cancer-testis antigen called PRAME (preferentially expressed antigen in melanoma) has been shown to increase metastatic risks in both low-risk and high-risk melanomas. New therapeutic approaches, including molecular therapies and nanoparticle phototherapy, are currently being investigated as alternative treatment modalities for uveal melanoma. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> retinoblastoma, uveal melanoma, ocular tumors </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Amy C Schefler (<a href="mailto:acsmd@houstonretina.com">acsmd@houstonretina.com</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Amy C Schefler </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2018 Schefler AC and Kim RS. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Schefler AC and Kim RS. Recent advancements in the management of retinoblastoma and uveal melanoma [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):476 (<a href="https://doi.org/10.12688/f1000research.11941.1" target=_blank>https://doi.org/10.12688/f1000research.11941.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 18 Apr 2018, <b>7</b>(F1000 Faculty Rev):476 (<a href="https://doi.org/10.12688/f1000research.11941.1" target=_blank>https://doi.org/10.12688/f1000research.11941.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 18 Apr 2018, <b>7</b>(F1000 Faculty Rev):476 (<a href="https://doi.org/10.12688/f1000research.11941.1" target=_blank>https://doi.org/10.12688/f1000research.11941.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d4312e182>Introduction</h2><p class="" id=d4312e185>Retinoblastoma and uveal melanoma, albeit rare, are the most commonly observed intraocular malignancies in pediatric and adult populations, respectively. Retinoblastoma occurs during early childhood in 1 per 16,000 people worldwide<sup><a href="#ref-1">1</a></sup>, whereas uveal melanoma occurs on average in Caucasians in their fifties and sixties<sup><a href="#ref-2">2</a></sup>. Recent advancements in the techniques used to treat these two types of cancer have drastically enhanced patient outcomes and eye salvage rates. In this review, we briefly discuss current treatment guidelines and some emerging topics in the management of primary retinoblastoma and primary uveal melanoma.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4312e199>Retinoblastoma</h2><p class="" id=d4312e202>Retinoblastoma presents unilaterally in approximately 60–70% of cases and bilaterally in the remaining 30–40%. In unilateral retinoblastoma, close to 90% of patients present with a sporadic mutation, whereas heritable mutations of the <i>RB1</i> gene (located at chromosome 13q14) with a known affected family member occur in approximately 10% (<a href="#T1">Table 1</a>)<sup><a href="#ref-3">3</a>,<a href="#ref-4">4</a></sup>. A small fraction of non-heritable retinoblastoma presents with a <i>MYCN</i> oncogene mutation that results in a unilateral, sporadic tumor<sup><a href="#ref-5">5</a></sup>. Unlike unilateral disease, bilateral retinoblastoma is always due to a germline mutation and commonly presents earlier in life than unilateral cases. With the advent of improved sequencing techniques, mosaicism is increasingly being recognized in both unilateral and bilateral patients. The presence of a germline <i>RB1</i> mutation increases the risk for secondary cancers, especially when retinoblastoma is treated with external beam radiation (EBR)<sup><a href="#ref-6">6</a></sup>.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Comparison of characteristics between sporadic and hereditary retinoblastoma.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d4312e244 class=n-a></a><thead><a name=d4312e246 class=n-a></a><tr><a name=d4312e248 class=n-a></a><th align=left colspan=1 rowspan=1><a name=d4312e250 class=n-a></a></th><th align=left colspan=1 rowspan=1 valign=top><a name=d4312e252 class=n-a></a>Sporadic</th><th align=left colspan=1 rowspan=1 valign=top><a name=d4312e255 class=n-a></a>Germline</th><th align=left colspan=1 rowspan=1 valign=top><a name=d4312e258 class=n-a></a>Germline-<br class=br>mosaic</th></tr></thead><tbody><a name=d4312e265 class=n-a></a><tr><a name=d4312e267 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e269 class=n-a></a>Number of mutated cells</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e272 class=n-a></a>One</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e275 class=n-a></a>All</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e278 class=n-a></a>Variable</td></tr><tr><a name=d4312e282 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e284 class=n-a></a>Laterality</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e287 class=n-a></a>Always<br class=br>unilateral</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e292 class=n-a></a>85% bilateral,<br class=br>15% unilateral</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e297 class=n-a></a>Either unilateral<br class=br>or bilateral</td></tr><tr><a name=d4312e303 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e305 class=n-a></a>Age of onset</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e308 class=n-a></a>18–24 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e311 class=n-a></a>12–18 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e314 class=n-a></a>Variable</td></tr><tr><a name=d4312e318 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e320 class=n-a></a>Chance of inheritance to<br class=br>offspring</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e325 class=n-a></a>0%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e328 class=n-a></a>45%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e331 class=n-a></a>Variable</td></tr></tbody></table></div><p class="" id=d4312e338>Both the Reese–Ellsworth and the International Classification of Retinoblastoma (ICRB) systems can be used to classify retinoblastoma, although the latter, newer system has been widely adopted in the last decade (<a href="#T2">Table 2</a>). ICRB divides retinoblastoma into five categories; class A is the least advanced and E is the most advanced type<sup><a href="#ref-7">7</a></sup>. Focal therapies such as laser ablation and cryotherapy can be used for retinoblastoma with ICRB classes A and B, whereas more advanced cases (ICRB class C, D, or E) are preferentially treated with systemic chemotherapy or intra-arterial chemotherapy (IAC) over EBR or plaque brachytherapy because of their adverse effects. Enucleation of the eye is performed when there is a potential risk of extraocular extension, especially in class E eyes, or when all prior treatments have failed.</p><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Summary of Reese–Ellsworth and International Classification of Retinoblastoma (ICRB) classification systems.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d4312e359 class=n-a></a><thead><a name=d4312e361 class=n-a></a><tr><a name=d4312e363 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d4312e365 class=n-a></a>Reese–Ellsworth classification</th><th align=left colspan=1 rowspan=1 valign=top><a name=d4312e368 class=n-a></a>International Classification of Retinoblastoma</th></tr></thead><tbody><a name=d4312e373 class=n-a></a><tr><a name=d4312e375 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e377 class=n-a></a>Group 1<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-&nbsp;&nbsp;&nbsp;&nbsp;1a: solitary tumor less than 4 disc<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;diameter (DD) at or behind equator<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-&nbsp;&nbsp;&nbsp;&nbsp;1b: multiple tumors all under<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 DD at or behind equator</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e388 class=n-a></a>Group A: tumors &lt;3 mm and away from fovea and optic disc</td></tr><tr><a name=d4312e392 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e394 class=n-a></a>Group 2<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-&nbsp;&nbsp;&nbsp;&nbsp;2a: solitary tumor 4–10 DD<br class=br>at &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;or behind equator<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-&nbsp;&nbsp;&nbsp;&nbsp;2b: multiple tumors 4–10 DD at or<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;behind equator</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e405 class=n-a></a>Group B: tumors &gt;3 mm, located at macula/peripapillary region, or with<br class=br>subretinal fluid</td></tr><tr><a name=d4312e411 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e413 class=n-a></a>Group 3<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-&nbsp;&nbsp;&nbsp;&nbsp;3a: tumors anterior to equator<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-&nbsp;&nbsp;&nbsp;&nbsp;3b: solitary tumor &gt;10 DD behind the<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;equator</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e422 class=n-a></a>Group C: tumors with focal vitreous or subretinal seeds within 3 mm of<br class=br>tumor</td></tr><tr><a name=d4312e428 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e430 class=n-a></a>Group 4<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-&nbsp;&nbsp;&nbsp;&nbsp;4a: multiple tumors with some &gt;10 DD<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-&nbsp;&nbsp;&nbsp;&nbsp;4b: any tumor extending to ora serrata</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e437 class=n-a></a>Group D: tumors with diffuse vitreous or subretinal seeds &gt;3 mm away from<br class=br>tumor</td></tr><tr><a name=d4312e443 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e445 class=n-a></a>Group 5<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-&nbsp;&nbsp;&nbsp;&nbsp;5a: tumors involving &gt;50% of retina<br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-&nbsp;&nbsp;&nbsp;&nbsp;5b: tumors with vitreous seeding</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e452 class=n-a></a>Group E: tumors covering &gt;50% of globe with or without neovascular<br class=br>glaucoma, hemorrhage, extension of tumor to optic nerve/anterior chamber</td></tr></tbody></table></div><div class=section><a name=d4312e462 class=n-a></a><h3 class=section-title>Intra-arterial chemotherapy as primary treatment</h3><p class="" id=d4312e467>EBR was used as primary therapy for retinoblastoma in most cases until the early 1990s and then intravenous chemotherapy (IVC) until the early 2000s. In 2004, a group of Japanese investigators reported a new technique of balloon-occluding the internal carotid artery distal to the ostium of the ophthalmic artery and then locally injecting melphalan to treat retinoblastoma<sup><a href="#ref-8">8</a></sup>. In 2008, Abramson <i>et al</i>. reported a more sophisticated technique of directly infusing melphalan into the ophthalmic artery with a microcatheter that many centers have now adopted with variations<sup><a href="#ref-9">9</a></sup>. In this report, seven out of 10 eyes classified as Reese–Ellsworth V and originally scheduled for enucleation were salvaged by IAC. Numerous studies have since reported on the efficacy of IAC compared with that of IVC. In one study by Shields <i>et al</i>.<sup><a href="#ref-10">10</a></sup>, global salvage rates for IAC and IVC for class D tumors were 91% and 48%, respectively, demonstrating that IAC can be particularly successful at treating more advanced tumors. Therefore, at many large centers of excellence, IAC is the preferred treatment modality for unilateral and non-hereditary retinoblastoma. Bilateral retinoblastoma with a germline <i>RB1</i> mutation can be treated with either systemic chemotherapy or tandem IAC, in which IAC is performed in both eyes in a single IAC session<sup><a href="#ref-11">11</a></sup>. In case the ophthalmic artery anatomy is not amenable to IAC, the external carotid artery can be alternately used to gain access to the ocular vasculature<sup><a href="#ref-12">12</a></sup>. Most large centers have reported superior ocular salvage rates with IAC compared with systemic chemotherapy (<a href="#f1">Figure 1</a>). Systemic treatment-related immediate effects such as immunosuppression are also rarer with IAC<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup>. Clinicians at centers that continue to use systemic chemotherapy have reported concerns about increased risks of metastatic retinoblastoma and risks of secondary cancers<sup><a href="#ref-15">15</a>,<a href="#ref-16">16</a></sup>. However, these controversies are unresolved with both fierce advocates and staunch opponents of IAC in existence with no clear sign of a definitive multi-center collaborative trial in the works that might settle the debate. As such, there continues to be a heterogeneity of treatment approaches in the US and abroad.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/12907/59ff6729-80b8-47f1-8144-ba81f339a70c_figure1.gif"><img alt="59ff6729-80b8-47f1-8144-ba81f339a70c_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/12907/59ff6729-80b8-47f1-8144-ba81f339a70c_figure1.gif"></a><div class=caption><h3>Figure 1. Retinoblastoma of a 5-month-old patient before and after intra-arterial chemotherapy (IAC).</h3><p id=d4312e527>(<b>a</b>) Fundus photograph of the right eye before IAC, demonstrating macular and inferonasal lesions. (<b>b</b>) Fundus photograph of the same eye 13 months after the initial IAC treatment. The patient underwent three IAC cycles and adjuvant therapy, including five sessions of laser ablation and two sessions of cryotherapy.</p></div></div><p class="" id=d4312e540>In many centers, IAC has been widely adopted as the primary therapy for retinoblastoma, and numerous publications have reported successful treatment outcomes. One of the recent reports, by Abramson <i>et al</i>., demonstrated that over 90% of patients now undergo IAC for primary therapy, and the global salvage rate at 48 months post-IAC significantly increased, from 68% in the late 2000s to 92.7% between 2010 and 2014<sup><a href="#ref-17">17</a></sup>. Shields <i>et al</i>. reported 100% ocular salvage for ICRB class B and C eyes, for which IAC was used as primary treatment<sup><a href="#ref-18">18</a></sup>. IAC has also been demonstrated to be highly efficacious for advanced tumors, and 5-year ocular survival exceeded 70% for class D tumors<sup><a href="#ref-18">18</a>–<a href="#ref-20">20</a></sup>. Class E tumors show mixed results: ocular salvage ranged from 30% to 70% in the literature<sup><a href="#ref-18">18</a>–<a href="#ref-20">20</a></sup>.</p></div><div class=section><a name=d4312e573 class=n-a></a><h3 class=section-title>Age and weight threshold for intra-arterial chemotherapy</h3><p class="" id=d4312e578>Whereas the safety and efficacy of IAC have been well demonstrated in multiple studies over the past decade, the guideline for age and weight threshold for IAC has not yet been strictly defined. It has generally been assumed that IAC should be reserved until patients with retinoblastoma reach a weight of 10 kg or the equivalent age because of potential procedural complications, such as groin hematomas or femoral artery dissection<sup><a href="#ref-21">21</a></sup>. However, several studies have recently demonstrated that patients with retinoblastoma who are younger than 3 months of age can be successfully treated with IAC<sup><a href="#ref-22">22</a>,<a href="#ref-23">23</a></sup>. The safety of IAC can be further enhanced with ultrasound guidance for femoral artery catheterization, which has long been used in various kinds of pediatric procedures. A pilot study of six patients with retinoblastoma<sup><a href="#ref-24">24</a></sup> demonstrated no procedural complications when IAC was administered with ultrasound guidance to patients with a median weight of 9.2 kg at the first IAC cycle. Recent literature suggests that younger and treatment-naïve patients may achieve better oncologic efficacy when they receive a minimal number of IAC cycles<sup><a href="#ref-25">25</a>,<a href="#ref-26">26</a></sup>. Also, Gobin <i>et al</i>. reported that eyes that received IAC as primary treatment had an ocular event-free survival rate of 81.7% after 2 years, which was significantly higher than the rate of 58.4% for the eyes that had undergone IVC or EBR prior to IAC<sup><a href="#ref-27">27</a></sup>. Therefore, unless there are known contraindications for IAC, such as metastatic retinoblastoma, optimal treatment outcomes may be achieved when the patients undergo IAC at the earliest age possible.</p></div><div class=section><a name=d4312e612 class=n-a></a><h3 class=section-title>Intravitreal melphalan for treating vitreous seeds</h3><p class="" id=d4312e617>Vitreous seeds are groups of tumor cells that break off from the primary lesion and are commonly seen in advanced retinoblastoma. Vitreous seeds are seen in ICRB class C, D, and E. Dust, spheres, and clouds are the three forms of vitreous seeds with different patterns of response to chemotherapy which have been previously characterized<sup><a href="#ref-28">28</a></sup>. IAC has limited efficacy for vitreous seeds because of the avascular nature of the vitreous. Intravitreal injections of chemotherapy via the pars plana have now been widely adopted for persistent or recurrent vitreous seeds after primary treatment with IAC or systemic chemotherapy<sup><a href="#ref-28">28</a>–<a href="#ref-30">30</a></sup>. In general, intravitreal melphalan or topotecan is combined with a simultaneous treatment of the retinal tumors from which the vitreous seeds originate. To prevent any potential extension of tumor seeds via the needle tract, clinicians typically take various safety measures, including cryotherapy applied to the needle site, visualization of the pars plana with ultrasound biomicroscopy, washing of the ocular surface, and subconjunctival chemotherapy<sup><a href="#ref-30">30</a>,<a href="#ref-31">31</a></sup>. The safety and efficacy of intravitreal injection of melphalan have been demonstrated in multiple studies<sup><a href="#ref-28">28</a>,<a href="#ref-32">32</a></sup>.</p></div><div class=section><a name=d4312e646 class=n-a></a><h3 class=section-title>Intravenous chemotherapy</h3><p class="" id=d4312e651>IVC has been used as primary and secondary therapy for retinoblastoma for over two decades. A three-agent combination (carboplatin, vincristine, and etoposide) is commonly used<sup><a href="#ref-33">33</a></sup>, and other agents, including topotecan or cisplatin, can be additionally administered depending on the patient’s response to the agents<sup><a href="#ref-34">34</a></sup>. Multiple studies report that over 90% of tumor control was achieved by using IVC, especially for ICRB classes A, B, and C<sup><a href="#ref-10">10</a>,<a href="#ref-35">35</a></sup>. IVC can be effective at managing both bilateral and germline retinoblastoma. Some investigators have reported that IVC helps in preventing extraocular secondary cancers, including trilateral retinoblastoma in which extraocular cancer occurs in the pineal or suprasellar region<sup><a href="#ref-36">36</a>–<a href="#ref-38">38</a></sup>; however, this is controversial. There are some rare but recognized side effects of IVC, including neurotoxicity, immunosuppression, secondary leukemia, nephrotoxicity, and ototoxicity<sup><a href="#ref-34">34</a></sup>.</p></div><div class=section><a name=d4312e681 class=n-a></a><h3 class=section-title>Radioactive plaque for persistent, recurrent retinoblastoma</h3><p class="" id=d4312e686>Owing to concerns for radiation retinopathy, radioactive plaque brachytherapy is most commonly used as rescue therapy for relatively small solitary tumors in ICRB class A or B<sup><a href="#ref-39">39</a>,<a href="#ref-40">40</a></sup>. However, plaque brachytherapy is one of the preferred secondary treatment modalities before enucleation. There have been published studies that demonstrated the efficacy of iodine-125 plaque brachytherapy as salvage treatment for retinoblastoma after both IAC and IVC<sup><a href="#ref-39">39</a>,<a href="#ref-40">40</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4312e707>Uveal melanoma</h2><p class="" id=d4312e710>Uveal melanoma is a malignant cancer that occurs in 4.9 people per million in the US alone<sup><a href="#ref-41">41</a></sup>. As the name suggests, uveal melanoma can occur in any part of the uveal tract, including the iris, ciliary body, or choroid, and the involvement of the choroid is the most common. Uveal melanoma is known to spread hematogenously, and the most common sites of metastasis in descending order are liver, lung, and bone<sup><a href="#ref-42">42</a></sup>. Mean overall 5-year survival rate has remained stable at approximately 80% over the past several decades<sup><a href="#ref-2">2</a>,<a href="#ref-43">43</a></sup>, while the 5-year survival rate drastically decreases once the tumor metastasizes. Lifetime rates of metastases in patients with uveal melanoma are controversial, but rates reported in the scientific literature range from 25% to 50% with a median survival of 6 months to a year after the development of metastatic disease<sup><a href="#ref-44">44</a>–<a href="#ref-46">46</a></sup>. Some studies have reported a longer median survival once metastatic disease is diagnosed, but other authors claim that lead-time bias explains these results<sup><a href="#ref-47">47</a></sup>. Upon initial diagnosis, most patients currently receive plaque brachytherapy, proton beam therapy, or enucleation, except for some iris tumors that can be surgically resected.</p><div class=section><a name=d4312e739 class=n-a></a><h3 class=section-title>Genetic and histopathologic analyses of uveal melanoma</h3><p class="" id=d4312e744>Uveal melanoma is largely due to sporadic mutations in uveal melanocytes, and inherited germline mutations that contribute to the development of this tumor are extremely rare, occurring in 3% to 4% of patients<sup><a href="#ref-48">48</a></sup>. However, a number of publications since the early 1990s have discussed the importance of cytogenetic changes of the cancer cells which significantly affect the prognosis. Uveal melanoma is histopathologically characterized by spindle and epithelioid cells<sup><a href="#ref-49">49</a></sup>. Standard cytology procedures, including cell block analysis with hematoxylin–eosin stain and HMB45/Ki67 immunohistochemical stain, can identify cells acquired from biopsies. Although epithelioid cells are strongly associated with more aggressive behavior, most uveal melanomas contain mixed spindle and epithelioid cells regardless of the predisposed metastatic risk<sup><a href="#ref-49">49</a></sup>. One study published that epithelioid and necrotic cell types have a statistically significantly higher rate of 5-year metastatic mortality rate than other cell-type findings<sup><a href="#ref-50">50</a></sup>. In the same study, cytopathologic classification was found to be an independent prognostic factor for metastatic death<sup><a href="#ref-50">50</a></sup>.</p><p class="" id=d4312e767>In the early 1990s, Prescher <i>et al</i>. first reported that monosomy 3, the abnormal presence of only one copy of chromosome 3, was a commonly observed cytogenetic abnormality in uveal melanoma<sup><a href="#ref-51">51</a></sup>. Since then, a number of studies focusing on the genetics of uveal melanoma have been published. Several key driver genes, including <i>GNA11</i>, <i>GNAQ</i>, <i>BAP1</i>, <i>SF3B1</i>, and <i>EIF1AX</i>, have been identified to be involved in the development and metastasis of the cancer<i></i><sup><a href="#ref-52">52</a></sup>. Combinations of mutations of these genes lead to variations in the development and metastasis of uveal melanoma. Of these, <i>GNAQ</i> and <i>GNA11</i> mutations are involved in the early stage of oncogenesis and occur in a mutually exclusive manner in approximately 91% of the patients<sup><a href="#ref-53">53</a></sup>. Because these mutations occur early in oncogenesis, neither one confers valuable prognostic information. Recently, a loss-of-function mutation of <i>BAP1</i>, a tumor suppressor gene, was discovered to be heavily associated with more malignant types of uveal melanoma. Loss of <i>BAP1</i> induces dedifferentiation of melanoma cells and the development of stem cell-like characteristics<sup><a href="#ref-54">54</a>,<a href="#ref-55">55</a></sup>. On the other hand, hemizygous, gain-of-function mutations of <i>SF3B1</i> and <i>EIF1AX</i> generally indicate a better prognosis and occur in lower-risk melanomas<sup><a href="#ref-56">56</a></sup>. Of note, melanomas with <i>SF3B1</i> mutations are associated with late-onset metastases<sup><a href="#ref-57">57</a></sup>. <i>BAP1</i>, <i>SF3B1</i>, and <i>EIF1AX</i> mutations mostly occur late in tumor development and also occur in a mutually exclusive fashion<sup><a href="#ref-58">58</a></sup>.</p><p class="" id=d4312e854>Gene expression profile (GEP) analysis and multiplex ligand-dependent probe amplification (MLPA) have been adopted by ocular oncologists to elucidate each tumor’s genetic characteristics<sup><a href="#ref-59">59</a>,<a href="#ref-60">60</a></sup>. GEP testing uses a polymerase chain reaction (PCR)-based 15-gene panel and classifies uveal melanoma as either class 1 (low risk for metastasis) or class 2 (high risk for metastasis)<sup><a href="#ref-59">59</a>,<a href="#ref-61">61</a></sup>. Class 1 is further divided into 1A and 1B; 1A tumors remain relatively low-risk for metastasis, whereas the risk of metastasizing in 1B appears to be higher than the 1A group over time. The 5-year published metastatic rates for class 1A, 1B, and 2 tumors are 2%, 21%, and 72%, respectively<sup><a href="#ref-58">58</a></sup>. It has been observed that class 1B uveal melanoma, though categorized under class 1, behaves more similarly to class 2 tumors and therefore requires close monitoring for progression to metastasis. <i>BAP1</i> somatic mutations are observed predominantly in class 2 tumors, whereas <i>SF3B1</i> or <i>EIF1AX</i> mutations are seen more frequently in class 1 tumors<sup><a href="#ref-54">54</a></sup>. It is reported that <i>BAP1</i> mutations can be observed in approximately 80% of metastatic uveal melanoma cells<sup><a href="#ref-54">54</a></sup>. In another study, 71%, 11%, and 0% of patients with primary uveal melanoma who developed metastases carried <i>BAP1</i>, <i>SF3B1</i>, and <i>EIF1AX</i> mutations, respectively, signifying that <i>EIF1AX</i> and <i>SF3B1</i> mutations generally confer a good prognosis<sup><a href="#ref-62">62</a></sup>. In the largest single-institution case series of over 1,000 patients, 3-year Kaplan–Meier estimates for metastatic uveal melanoma were provided for the following cytogenetic abnormalities: 5% for partial monosomy of chromosome 3; 19% for complete monosomy 3; 23% for loss of 6q; 29% for loss of 8p; 21% for gain of 8q; 1% for disomy of 3, 6, and 8; 29% for complete monosomy 3, 6p gain, and 8q gain; 14% for complete monosomy of 3, disomy of 6, and gain of 8q and 8p; 27% for complete monosomy of 3, disomy of 6, and gain of 8q; and 28% for complete monosomy of 3, disomy of 6, gain of 8q, and loss of 8p<sup><a href="#ref-63">63</a></sup>.</p><p class="" id=d4312e920>Recently, scientists have discovered that certain uveal melanomas that express a cancer-testis antigen called preferentially expressed antigen in melanoma (PRAME) are closely associated with an increased risk of metastasis in both class 1 and 2 uveal melanomas<sup><a href="#ref-64">64</a>,<a href="#ref-65">65</a></sup>. Also, class 1 tumors that are PRAME<sup>+</sup> were found to be associated with <i>SF3B1</i> mutations and inversely to <i>EIF1AX</i> mutations<sup><a href="#ref-65">65</a></sup>. A combination of <i>SF3B1</i> mutations and PRAME expression appears to contribute to late metastases in class 1 tumors<sup><a href="#ref-66">66</a></sup>, while PRAME<sup>+</sup> class 2 tumors exhibited accelerated progression to metastases<sup><a href="#ref-65">65</a></sup>. PRAME is currently being investigated as a potential target for immunotherapy in primary and metastatic uveal melanoma<sup><a href="#ref-67">67</a></sup>. The Collaborative Ocular Oncology Group 2 (COOG2) is a currently enrolling multi-center prospective clinical trial in which PRAME genomics will be examined along with long-term clinical outcomes.</p></div><div class=section><a name=d4312e963 class=n-a></a><h3 class=section-title>Fine needle aspiration biopsy</h3><p class="" id=d4312e968>As research in melanoma genomics has grown explosively, safe and adequate acquisition of tumor cells has become increasingly important for both clinical and research purposes. Fine needle aspiration biopsy (FNAB) is performed by using small-sized needles (23-, 25-, or 27-gauge) or vitrectomy probes in either a transvitreal or a trans-scleral manner, depending on the tumor location. For tumors that are anterior to the equator with direct access to the needle, the trans-scleral method is typically chosen. For posterior tumors that are more difficult to access via a trans-scleral biopsy, transvitreal biopsy can be performed by using indirect ophthalmoscopy or standard retinal instrumentation, including chandelier lighting that gives direct visualization, and valved trocars, which serve to maintain the intraocular pressure during biopsy and prevent the tracking of tumor cells along the needle tract. After the aspiration of tumor cells, cryotherapy is applied to the needle insertion site in order to prevent any iatrogenic extraocular extension of tumor cells via the needle tract. Safety of FNAB for uveal melanoma was recently reaffirmed in a prospective, <i>in vivo</i> study<sup><a href="#ref-68">68</a></sup>. Many studies have demonstrated high cellular yield rates, ranging from 68% to over 90%, for cytopathologic and genomic analyses<sup><a href="#ref-69">69</a>–<a href="#ref-73">73</a></sup>.</p></div><div class=section><a name=d4312e986 class=n-a></a><h3 class=section-title>Plaque brachytherapy</h3><p class="" id=d4312e991>The Collaborative Ocular Melanoma Study (COMS) found no statistically significant difference in survival between patients who underwent plaque brachytherapy and patients who underwent enucleation<sup><a href="#ref-74">74</a></sup>. Since then, most centers have adopted plaque brachytherapy as the standard treatment for uveal melanoma. Multiple types of isotopes are used for ophthalmic brachytherapy. In the US, <sup>125</sup>I is the most frequently used radioisotope after the COMS study, whereas <sup>106</sup>Ru and <sup>103</sup>Pd are more commonly used in Europe and other countries<sup><a href="#ref-75">75</a></sup>. <sup>125</sup>I and <sup>103</sup>Pd both emit low-energy gamma rays and thus cause less damage to surrounding healthy tissues compared with isotopes that were used in the first half of the 20th century, such as <sup>60</sup>Co. <sup>106</sup>Ru, on the other hand, emits beta rays and has a quicker dose fall-off<sup><a href="#ref-75">75</a></sup>. The steeper the dose gradient, the more concentrated the radiation effect on the basal side of the tumor and conversely less radiation toward the apex. <sup>106</sup>Ru has an advantage of less radiation effect to other ocular structures compared with that of <sup>125</sup>I or <sup>103</sup>Pd.</p><p class="" id=d4312e1038>Multiple studies have demonstrated that plaque therapy and enucleation result in comparable mortality rates over 20 years of follow-up<sup><a href="#ref-76">76</a></sup>. Iodine-125 brachytherapy has become the most commonly used treatment modality for uveal melanoma in the US with excellent clinical outcomes (<a href="#f2">Figure 2</a>).</p><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/12907/59ff6729-80b8-47f1-8144-ba81f339a70c_figure2.gif"><img alt="59ff6729-80b8-47f1-8144-ba81f339a70c_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/12907/59ff6729-80b8-47f1-8144-ba81f339a70c_figure2.gif"></a><div class=caption><h3>Figure 2. Uveal melanoma of a 66-year-old patient before and after plaque brachytherapy.</h3><p id=d4312e1058>(<b>a</b>) B-scan ultrasound image of the right eye before the plaque implantation. (<b>b</b>) B-scan ultrasound image of the same eye intraoperatively, demonstrating full coverage of the tumor with the plaque. (<b>c</b>) B-scan ultrasound image of the same eye 3 years after the plaque therapy, demonstrating regression of the tumor.</p></div></div><p class="" id=d4312e1074>Local recurrence of tumor cells at the ocular site is a critical complication to be avoided after plaque therapy. Multiple studies have demonstrated that the likelihood of metastasis increases dramatically after local recurrence occurs<sup><a href="#ref-77">77</a>,<a href="#ref-78">78</a></sup>. However, the 5-year local recurrence rate has steadily decreased from 10.3% at the time of the COMS<sup><a href="#ref-76">76</a></sup> to 2.4% to approximately 4.7%<sup><a href="#ref-77">77</a>,<a href="#ref-79">79</a></sup> over the past two decades. Indeed, a recent publication that reported preliminary clinical outcomes with a median follow-up of 21.6 months<sup><a href="#ref-80">80</a></sup> demonstrated zero local recurrence, which may be attributed to several factors. First, newer plaque designs<sup><a href="#ref-81">81</a>,<a href="#ref-82">82</a></sup> are thinner than the traditional COMS plaques and are customized to conform better to each patient’s eye, leading to better coverage of the tumor and less radiation scatter outside the targeted area. Second, intraoperative ultrasonographic confirmation of plaque positioning, which has been used more over the past decade, ensures precise placement of the plaque<sup><a href="#ref-83">83</a>–<a href="#ref-85">85</a></sup>. A recent study at the Cleveland Clinic reported that plaque treatment failure decreased from 9.3% to 1.5% since intraoperative ultrasound was adopted<sup><a href="#ref-86">86</a></sup>. Intraoperative transillumination of the tumor and preoperative 3D planning with Plaque Simulation software can further enhance the accuracy of plaque placement<sup><a href="#ref-80">80</a>,<a href="#ref-87">87</a></sup>. Treatment outcomes of plaque brachytherapy, including 5-year mortality and local recurrence rates (4%), are comparable to those of proton beam radiotherapy in recent publications<sup><a href="#ref-88">88</a>,<a href="#ref-89">89</a></sup>. Both plaque and proton beam therapy are known to cause ocular complications, including cataracts, radiation retinopathy, and radiation optic neuropathy. The COMS demonstrated that nearly 50% of patients who receive plaque brachytherapy had significant vision loss by 3 years post-treatment because of these complications<sup><a href="#ref-90">90</a></sup>.</p></div><div class=section><a name=d4312e1138 class=n-a></a><h3 class=section-title>Clinical features with prognostic significance</h3><p class="" id=d4312e1143>In addition to the fact that GEP class 2 melanomas have higher mortality rates than GEP class 1 tumors, several additional factors that contribute valuable prognostic information have recently been identified. Correa and Augsburger recently reported that the largest basal diameter (LBD) of the tumor can serve as an independent prognostic factor for metastasis and metastatic death<sup><a href="#ref-91">91</a></sup>. Harbour <i>et al</i>. reported that class 2 tumors with an LBD over 12 mm had a significantly lower 5-year metastasis-free survival<sup><a href="#ref-92">92</a></sup>. Also, increased patient age, larger tumor apical height, and ciliary body involvement of the tumor are associated with metastatic risk<sup><a href="#ref-93">93</a>,<a href="#ref-94">94</a></sup>. Traditionally, tumors with more malignant characteristics, such as tumors with monosomy 3 or those that metastasized, were reported to regress faster after plaque therapy<sup><a href="#ref-95">95</a>,<a href="#ref-96">96</a></sup>. In recent studies, the relationship between GEP class and the tumor regression rate after brachytherapy has been controversial. Whereas several studies<sup><a href="#ref-97">97</a>,<a href="#ref-98">98</a></sup> found neither GEP class to be significantly associated with regression rate, another study reported that class 1 tumors regress faster<sup><a href="#ref-99">99</a></sup>. In the largest multi-center, retrospective cohort study that was recently published, investigators also reported that class 1 tumors regress at a statistically significantly faster rate than class 2 tumors after plaque radiation<sup><a href="#ref-100">100</a></sup>. Future multi-center studies will help elucidate a clearer relationship between GEP class and therapeutic response to radiation.</p></div><div class=section><a name=d4312e1188 class=n-a></a><h3 class=section-title>Molecular therapies</h3><p class="" id=d4312e1193>Some recent studies have identified several key molecular pathways associated with specific genetic mutations. For example, the <i>BAP1</i> gene is known to regulate histone H2A function by removing ubiquitin molecules. When the <i>BAP1</i> gene is mutated, proper removal of ubiquitin from H2A is inhibited, leading to a dedifferentiated state of melanoma cells<sup><a href="#ref-101">101</a></sup>. Also, <i>GNAQ</i> and <i>GNA11</i> genes are closely related to transmembrane cell signaling<sup><a href="#ref-52">52</a></sup>. Activation mutation of <i>GNAQ</i> or <i>GNA11</i> keeps guanine nucleotide-binding proteins in an active state, which subsequently upregulates protein kinase C and mitogen-activated protein kinase pathways that are involved in the proliferation and differentiation of cells at the early stages of uveal melanoma oncogenesis<sup><a href="#ref-102">102</a></sup>. Many ongoing clinical trials (some of which are still accruing patients and some of which are now closed to new patient enrollment) are examining immunotherapy agents that target these pathways as well as several others for both high-risk and metastatic uveal melanoma (<a href="#T3">Table 3</a> and <a href="#T4">Table 4</a>).</p><a name=T3 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 3. List of ongoing clinical trials of adjuvant molecular therapy for high-risk uveal melanoma.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d4312e1244 class=n-a></a><thead><a name=d4312e1246 class=n-a></a><tr><a name=d4312e1248 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d4312e1250 class=n-a></a>ClinicalTrials.gov identifier</th><th align=left colspan=1 rowspan=1 valign=top><a name=d4312e1253 class=n-a></a>Study locations</th><th align=left colspan=1 rowspan=1 valign=top><a name=d4312e1256 class=n-a></a>Study title</th></tr></thead><tbody><a name=d4312e1261 class=n-a></a><tr><a name=d4312e1263 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1265 class=n-a></a>NCT02223819</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1268 class=n-a></a>Columbia University, New York, NY<br class=br><br class=br>Mount Sinai Comprehensive Cancer<br class=br>Center, Miami Beach, FL<br class=br><br class=br>Memorial Sloan Kettering Cancer Center,<br class=br>New York, NY<br class=br><br class=br>The Ohio State University, Columbus, OH</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1285 class=n-a></a>Crizotinib in High-Risk Uveal Melanoma<br class=br>Following Definitive Therapy</td></tr><tr><a name=d4312e1291 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1293 class=n-a></a>NCT02068586</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1296 class=n-a></a>Thomas Jefferson University,<br class=br>Philadelphia, PA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1301 class=n-a></a>Adjuvant Sunitinib or Valproic Acid in High-Risk<br class=br>Patients With Uveal Melanoma</td></tr></tbody></table></div><a name=T4 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 4. List of ongoing clinical trials of molecular therapy for metastatic uveal melanomas.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d4312e1321 class=n-a></a><thead><a name=d4312e1323 class=n-a></a><tr><a name=d4312e1325 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d4312e1327 class=n-a></a>ClinicalTrials.gov<br class=br>identifier</th><th align=left colspan=1 rowspan=1 valign=top><a name=d4312e1332 class=n-a></a>Study locations</th><th align=left colspan=1 rowspan=1 valign=top><a name=d4312e1335 class=n-a></a>Study title</th></tr></thead><tbody><a name=d4312e1340 class=n-a></a><tr><a name=d4312e1342 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1344 class=n-a></a>NCT01979523</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1347 class=n-a></a>Moffitt Cancer Center, Tampa, FL<br class=br><br class=br>Emory University/Winship Cancer Institute, Atlanta, GA<br class=br><br class=br>Columbia University/Herbert Irving Cancer Center, New York, NY<br class=br><br class=br>Memorial Sloan Kettering Cancer Center, New York, NY<br class=br><br class=br>Vanderbilt University/Ingram Cancer Center, Nashville, TN<br class=br><br class=br>MD Anderson Cancer Center, Houston, TX<br class=br><br class=br>Institut Curie Paris, Paris, France<br class=br><br class=br>The University of Liverpool, Liverpool, UK</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1372 class=n-a></a>Trametinib With or Without GSK2141795 in<br class=br>Treating Patients With Metastatic Uveal Melanoma</td></tr><tr><a name=d4312e1378 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1380 class=n-a></a>NCT01585194</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1383 class=n-a></a>University of Texas MD Anderson Cancer Center, Houston, TX</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1386 class=n-a></a>Phase II Study of Nivolumab in Combination With<br class=br>Ipilimumab for Uveal Melanoma</td></tr><tr><a name=d4312e1392 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1394 class=n-a></a>NCT02570308</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1397 class=n-a></a>Washington University, School of Medicine, St. Louis, MO<br class=br><br class=br>Columbia University Medical Center – The New York Presbyterian<br class=br>Hospital, New York, NY<br class=br><br class=br>Thomas Jefferson University Medical Oncology Clinic,<br class=br>Philadelphia, PA<br class=br><br class=br>The Clatterbridge Cancer Centre, Wirral, Merseyside, UK<br class=br><br class=br>Mount Vernon Cancer Centre, Northwood, Middlesex, UK</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1417 class=n-a></a>A Study of the Intra-Patient Escalation Dosing<br class=br>Regimen With IMCgp100 in Patients With<br class=br>Advanced Uveal Melanoma</td></tr><tr><a name=d4312e1425 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1427 class=n-a></a>NCT02359851</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1430 class=n-a></a>University of Chicago, Chicago, IL<br class=br><br class=br>Vanderbilt-Ingram Cancer Center, Nashville, TN</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1436 class=n-a></a>Pembrolizumab in Treating Patients With<br class=br>Advanced Uveal Melanoma</td></tr><tr><a name=d4312e1442 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1444 class=n-a></a>NCT02273219</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1447 class=n-a></a>Bascom Palmer Eye Institute of University Of Miami Medical<br class=br>Center, Miami, FL<br class=br><br class=br>Columbia University Medical Center, New York, NY<br class=br><br class=br>Memorial Sloan Kettering Cancer Center, New York, NY</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1458 class=n-a></a>Trial of AEB071 in Combination With BYL719 in<br class=br>Patients With Melanoma</td></tr><tr><a name=d4312e1465 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1467 class=n-a></a>NCT01473004</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1470 class=n-a></a>Thomas Jefferson University, Philadelphia, PA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1473 class=n-a></a>SIR-Spheres 90Y Microspheres Treatment of<br class=br>Uveal Melanoma Metastasized to Liver</td></tr><tr><a name=d4312e1479 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1481 class=n-a></a>NCT02678572</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1484 class=n-a></a>32 locations in the US, Austria, Belgium, France, Germany, Italy,<br class=br>Spain, Switzerland, and the UK</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1489 class=n-a></a>Percutaneous Hepatic Perfusion vs Best<br class=br>Alternative Care in Patients With Hepatic-<br class=br>dominant Ocular Melanoma (FOCUS)</td></tr><tr><a name=d4312e1497 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1499 class=n-a></a>NCT01814046</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1502 class=n-a></a>National Institutes of Health Clinical Center, Bethesda, MD</td><td align=left colspan=1 rowspan=1 valign=top><a name=d4312e1505 class=n-a></a>Immunotherapy Using Tumor Infiltrating<br class=br>Lymphocytes for Patients With Metastatic Ocular<br class=br>Melanoma</td></tr></tbody></table></div></div><div class=section><a name=d4312e1517 class=n-a></a><h3 class=section-title>Nanoparticle therapy</h3><p class="" id=d4312e1522>Nanoparticle therapy is an emerging cancer therapy, in which photosensitive nanoparticles preferentially bind tumor cells, followed by light activation of the nanoparticles<sup><a href="#ref-103">103</a></sup>. This is a minimally invasive yet highly specific treatment modality that can kill tumor cells with minimal damage to the surrounding normal tissues. For uveal melanoma, a phase 1b clinical trial has begun to investigate the safety of a new nanoparticle phototherapy for small to medium-sized tumors in 12 patients (<a target=xrefwindow href="http://www.aurabiosciences.com/news-archive/2017/3/30/aura-biosciences-announces-initiation-of-phase-1b-clinical-trial-and-receipt-of-fda-fast-track-designation-for-au-011-for-the-treatment-of-primary-ocular-melanoma" id=d4312e1528>http://www.aurabiosciences.com/news-archive/2017/3/30/aura-biosciences-announces-initiation-of-phase-1b-clinical-trial-and-receipt-of-fda-fast-track-designation-for-au-011-for-the-treatment-of-primary-ocular-melanoma</a>). Viral nanoparticle conjugates attach to the uveal melanoma cell membrane. When activated by a 589 nm laser, the particles selectively break down the tumor cell membrane without affecting adjacent tissues. This treatment modality, if proven successful in clinical trials, has the potential to preserve much of the patient’s vision and could be particularly groundbreaking in patients with small tumors that are close to critical ocular structures such as the optic nerve and the macula. The effect on rates of metastatic disease are still unknown.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d4312e1536>Conclusions</h2><p class="" id=d4312e1539>Extensive advancements have been made in the understanding and treatment of retinoblastoma and uveal melanoma over the past decade. Further knowledge of intraocular cancer genetics will lead to new clinical breakthroughs that will allow us to save more eyes and lives.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d4312e1 class=n-a></a><h2 class=main-title id=d4614>Competing interests</h2><p class=metadata-entry><a name=d4312e108 class=n-a></a><p id=d4312e110> The authors declare that they have no competing interests.</p></p></div><div class=back-section><a name=d4312e1 class=n-a></a><h2 class=main-title id=d4616>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d4312e1546 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d4952>References</h2><div class="section ref-list"><a name=d4312e1546 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d4312e1553 class=n-a></a>Dimaras H, Corson TW, Cobrinik D, <i> et al.</i>: Retinoblastoma. <i>Nat Rev Dis Primers.</i> 2015; <b>1</b>: 15021. <a target=xrefwindow id=d4312e1564 href="http://www.ncbi.nlm.nih.gov/pubmed/27189421">PubMed Abstract </a> | <a target=xrefwindow id=d4312e1567 href="http://dx.doi.org/10.1038/nrdp.2015.21">Publisher Full Text </a> | <a target=xrefwindow id=d4312e1571 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5744255">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d4312e1580 class=n-a></a>Singh AD, Turell ME, Topham AK: Uveal melanoma: trends in incidence, treatment, and survival. <i>Ophthalmology.</i> 2011; <b>118</b>(9): 1881–5. <a target=xrefwindow id=d4312e1588 href="http://www.ncbi.nlm.nih.gov/pubmed/21704381">PubMed Abstract </a> | <a target=xrefwindow id=d4312e1591 href="http://dx.doi.org/10.1016/j.ophtha.2011.01.040">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d4312e1600 class=n-a></a>Chantada G, Schaiquevich P: Management of retinoblastoma in children: current status. <i>Paediatr Drugs.</i> 2015; <b>17</b>(3): 185–98. <a target=xrefwindow id=d4312e1608 href="http://www.ncbi.nlm.nih.gov/pubmed/25742925">PubMed Abstract </a> | <a target=xrefwindow id=d4312e1611 href="http://dx.doi.org/10.1007/s40272-015-0121-9">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d4312e1620 class=n-a></a>Abramson DH, Schefler AC: Update on retinoblastoma. <i>Retina.</i> 2004; <b>24</b>(6): 828–48. <a target=xrefwindow id=d4312e1628 href="http://www.ncbi.nlm.nih.gov/pubmed/15579980">PubMed Abstract </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d4312e1637 class=n-a></a>Rushlow DE, Mol BM, Kennett JY, <i> et al.</i>: Characterisation of retinoblastomas without <i>RB1</i> mutations: genomic, gene expression, and clinical studies. <i>Lancet Oncol.</i> 2013; <b>14</b>(4): 327–34. <a target=xrefwindow id=d4312e1651 href="http://www.ncbi.nlm.nih.gov/pubmed/23498719">PubMed Abstract </a> | <a target=xrefwindow id=d4312e1655 href="http://dx.doi.org/10.1016/S1470-2045(13)70045-7">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d4312e1665 class=n-a></a>Moll AC, Imhof SM, Schouten-Van Meeteren AY, <i> et al.</i>: Second primary tumors in hereditary retinoblastoma: a register-based study, 1945–1997: is there an age effect on radiation-related risk? <i>Ophthalmology.</i> 2001; <b>108</b>(6): 1109–14. <a target=xrefwindow id=d4312e1676 href="http://www.ncbi.nlm.nih.gov/pubmed/11382638">PubMed Abstract </a> | <a target=xrefwindow id=d4312e1679 href="http://dx.doi.org/10.1016/S0161-6420(01)00562-0">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d4312e1688 class=n-a></a>Linn Murphree A: Intraocular retinoblastoma: the case for a new group classification. <i>Ophthalmol Clin North Am.</i> 2005; <b>18</b>(1): 41–53, viii. <a target=xrefwindow id=d4312e1696 href="http://www.ncbi.nlm.nih.gov/pubmed/15763190">PubMed Abstract </a> | <a target=xrefwindow id=d4312e1699 href="http://dx.doi.org/10.1016/j.ohc.2004.11.003">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d4312e1708 class=n-a></a>Yamane T, Kaneko A, Mohri M: The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. <i>Int J Clin Oncol.</i> 2004; <b>9</b>(2): 69–73. <a target=xrefwindow id=d4312e1716 href="http://www.ncbi.nlm.nih.gov/pubmed/15108036">PubMed Abstract </a> | <a target=xrefwindow id=d4312e1719 href="http://dx.doi.org/10.1007/s10147-004-0392-6">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d4312e1728 class=n-a></a>Abramson DH, Dunkel IJ, Brodie SE, <i> et al.</i>: A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. <i>Ophthalmology.</i> 2008; <b>115</b>(8): 1398–404, 1404.e1. <a target=xrefwindow id=d4312e1739 href="http://www.ncbi.nlm.nih.gov/pubmed/18342944">PubMed Abstract </a> | <a target=xrefwindow id=d4312e1742 href="http://dx.doi.org/10.1016/j.ophtha.2007.12.014">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726075669"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e1751 class=n-a></a>Shields CL, Jorge R, Say EA, <i> et al.</i>: Unilateral Retinoblastoma Managed With Intravenous Chemotherapy Versus Intra-Arterial Chemotherapy. Outcomes Based on the International Classification of Retinoblastoma. <i>Asia Pac J Ophthalmol (Phila).</i> 2016; <b>5</b>(2): 97–103. <a target=xrefwindow id=d4312e1762 href="http://www.ncbi.nlm.nih.gov/pubmed/26765038">PubMed Abstract </a> | <a target=xrefwindow id=d4312e1765 href="http://dx.doi.org/10.1097/APO.0000000000000172">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726075669">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726397967"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e1778 class=n-a></a>Abramson DH, Marr BP, Francis JH, <i> et al.</i>: Simultaneous Bilateral Ophthalmic Artery Chemosurgery for Bilateral Retinoblastoma (Tandem Therapy). <i>PLoS One.</i> 2016; <b>11</b>(6): e0156806. <a target=xrefwindow id=d4312e1789 href="http://www.ncbi.nlm.nih.gov/pubmed/27258771">PubMed Abstract </a> | <a target=xrefwindow id=d4312e1792 href="http://dx.doi.org/10.1371/journal.pone.0156806">Publisher Full Text </a> | <a target=xrefwindow id=d4312e1796 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4892546">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726397967">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d4312e1810 class=n-a></a>Abruzzo TA, Geller JI, Kimbrough DA, <i> et al.</i>: Adjunctive techniques for optimization of ocular hemodynamics in children undergoing ophthalmic artery infusion chemotherapy. <i>J Neurointerv Surg.</i> 2015; <b>7</b>(10): 770–6. <a target=xrefwindow id=d4312e1821 href="http://www.ncbi.nlm.nih.gov/pubmed/25179634">PubMed Abstract </a> | <a target=xrefwindow id=d4312e1824 href="http://dx.doi.org/10.1136/neurintsurg-2014-011295">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d4312e1833 class=n-a></a>Schefler AC, Kleinerman RA, Abramson DH: Genes and environment: effects on the development of second malignancies in retinoblastoma survivors. <i>Expert Rev Ophthalmol.</i> 2008; <b>3</b>(1): 51–61. <a target=xrefwindow id=d4312e1841 href="http://www.ncbi.nlm.nih.gov/pubmed/24904684">PubMed Abstract </a> | <a target=xrefwindow id=d4312e1844 href="http://dx.doi.org/10.1586/17469899.3.1.51">Publisher Full Text </a> | <a target=xrefwindow id=d4312e1847 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4043380">Free Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725948064"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e1856 class=n-a></a>Michaels ST, Abruzzo TA, Augsburger JJ, <i> et al.</i>: Selective Ophthalmic Artery Infusion Chemotherapy for Advanced Intraocular Retinoblastoma: CCHMC Early Experience. <i>J Pediatr Hematol Oncol.</i> 2016; <b>38</b>(1): 65–9. <a target=xrefwindow id=d4312e1867 href="http://www.ncbi.nlm.nih.gov/pubmed/26583615">PubMed Abstract </a> | <a target=xrefwindow id=d4312e1870 href="http://dx.doi.org/10.1097/MPH.0000000000000471">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725948064">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d4312e1883 class=n-a></a>Ramasubramanian A, Kytasty C, Meadows AT, <i> et al.</i>: Incidence of pineal gland cyst and pineoblastoma in children with retinoblastoma during the chemoreduction era. <i>Am J Ophthalmol.</i> 2013; <b>156</b>(4): 825–9. <a target=xrefwindow id=d4312e1894 href="http://www.ncbi.nlm.nih.gov/pubmed/23876864">PubMed Abstract </a> | <a target=xrefwindow id=d4312e1897 href="http://dx.doi.org/10.1016/j.ajo.2013.05.023">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726223937"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e1906 class=n-a></a>Yousef YA, Soliman SE, Astudillo PP, <i> et al.</i>: Intra-arterial Chemotherapy for Retinoblastoma: A Systematic Review. <i>JAMA Ophthalmol.</i> 2016; <b>134</b>(5): 584–591. <a target=xrefwindow id=d4312e1917 href="http://www.ncbi.nlm.nih.gov/pubmed/26986443">PubMed Abstract </a> | <a target=xrefwindow id=d4312e1920 href="http://dx.doi.org/10.1001/jamaophthalmol.2016.0244">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726223937">F1000 Recommendation</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d4312e1933 class=n-a></a>Abramson DH, Fabius AW, Issa R, <i> et al.</i>: Advanced Unilateral Retinoblastoma: The Impact of Ophthalmic Artery Chemosurgery on Enucleation Rate and Patient Survival at MSKCC. <i>PLoS One.</i> 2015; <b>10</b>(12): e0145436. <a target=xrefwindow id=d4312e1944 href="http://www.ncbi.nlm.nih.gov/pubmed/26709699">PubMed Abstract </a> | <a target=xrefwindow id=d4312e1947 href="http://dx.doi.org/10.1371/journal.pone.0145436">Publisher Full Text </a> | <a target=xrefwindow id=d4312e1951 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4692433">Free Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d4312e1961 class=n-a></a>Shields CL, Manjandavida FP, Lally SE, <i> et al.</i>: Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. <i>Ophthalmology.</i> 2014; <b>121</b>(7): 1453–60. <a target=xrefwindow id=d4312e1972 href="http://www.ncbi.nlm.nih.gov/pubmed/24656794">PubMed Abstract </a> | <a target=xrefwindow id=d4312e1975 href="http://dx.doi.org/10.1016/j.ophtha.2014.01.026">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727230177"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e1984 class=n-a></a>Abramson DH, Fabius AW, Francis JH, <i> et al.</i>: Ophthalmic artery chemosurgery for eyes with advanced retinoblastoma. <i>Ophthalmic Genet.</i> 2017; <b>38</b>(1): 16–21. <a target=xrefwindow id=d4312e1995 href="http://www.ncbi.nlm.nih.gov/pubmed/28095092">PubMed Abstract </a> | <a target=xrefwindow id=d4312e1998 href="http://dx.doi.org/10.1080/13816810.2016.1244695">Publisher Full Text </a> | <a target=xrefwindow id=d4312e2002 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5475401">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727230177">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727010225"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e2015 class=n-a></a>Chen M, Jiang H, Zhang J, <i> et al.</i>: Outcome of intra-arterial chemotherapy for retinoblastoma and its influencing factors: a retrospective study. <i>Acta Ophthalmol.</i> 2017; <b>95</b>(6): 613–8. <a target=xrefwindow id=d4312e2026 href="http://www.ncbi.nlm.nih.gov/pubmed/27874261">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2029 href="http://dx.doi.org/10.1111/aos.13333">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727010225">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d4312e2042 class=n-a></a>Gobin YP, Dunkel IJ, Marr BP, <i> et al.</i>: Combined, sequential intravenous and intra-arterial chemotherapy (bridge chemotherapy) for young infants with retinoblastoma. <i>PLoS One.</i> 2012; <b>7</b>(9): e44322. <a target=xrefwindow id=d4312e2053 href="http://www.ncbi.nlm.nih.gov/pubmed/23028521">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2056 href="http://dx.doi.org/10.1371/journal.pone.0044322">Publisher Full Text </a> | <a target=xrefwindow id=d4312e2060 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3445577">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726623859"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e2069 class=n-a></a>Chen M, Zhao J, Xia J, <i> et al.</i>: Intra-Arterial Chemotherapy as Primary Therapy for Retinoblastoma in Infants Less than 3 Months of Age: A Series of 10 Case-Studies. <i>PLoS One.</i> 2016; <b>11</b>(8): e0160873. <a target=xrefwindow id=d4312e2080 href="http://www.ncbi.nlm.nih.gov/pubmed/27504917">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2083 href="http://dx.doi.org/10.1371/journal.pone.0160873">Publisher Full Text </a> | <a target=xrefwindow id=d4312e2087 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4978489">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726623859">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733014929"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e2100 class=n-a></a>Magan T, Khoo CT, Jabbour PM, <i> et al.</i>: Intraarterial Chemotherapy for Retinoblastoma in A 2-Month-Old Infant. <i>Retin Cases Brief Rep.</i> 2017; <b>11</b>(1): 24–26. <a target=xrefwindow id=d4312e2111 href="http://www.ncbi.nlm.nih.gov/pubmed/26756523">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2114 href="http://dx.doi.org/10.1097/ICB.0000000000000279">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733014929">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d4312e2128 class=n-a></a>Kim RS, Dannenbaum MJ, Lin MW, <i> et al.</i>: Use of Femoral Artery Ultrasound During Intraarterial Chemotherapy for Children Under 10 kg With Retinoblastoma. <i>Retina.</i> 2017. <a target=xrefwindow id=d4312e2136 href="http://www.ncbi.nlm.nih.gov/pubmed/28541962">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2139 href="http://dx.doi.org/10.1097/IAE.0000000000001713">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13656957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e2148 class=n-a></a>Shields CL, Kaliki S, Shah SU, <i> et al.</i>: Minimal exposure (one or two cycles) of intra-arterial chemotherapy in the management of retinoblastoma. <i>Ophthalmology.</i> 2012; <b>119</b>(1): 188–92. <a target=xrefwindow id=d4312e2159 href="http://www.ncbi.nlm.nih.gov/pubmed/21975042">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2162 href="http://dx.doi.org/10.1016/j.ophtha.2011.06.036">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13656957">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727019901"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e2175 class=n-a></a>Dillon AB, Douglass A, Jabbour P, <i> et al.</i>: Minimal exposure intra-arterial chemotherapy for children with retinoblastoma and 13q syndrome. <i>Oman J Ophthalmol.</i> 2016; <b>9</b>(3): 164–166. <a target=xrefwindow id=d4312e2186 href="http://www.ncbi.nlm.nih.gov/pubmed/27843232">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2189 href="http://dx.doi.org/10.4103/0974-620X.192278">Publisher Full Text </a> | <a target=xrefwindow id=d4312e2193 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5084500">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727019901">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13296974"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e2206 class=n-a></a>Gobin YP, Dunkel IJ, Marr BP, <i> et al.</i>: Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. <i>Arch Ophthalmol.</i> 2011; <b>129</b>(6): 732–7. <a target=xrefwindow id=d4312e2217 href="http://www.ncbi.nlm.nih.gov/pubmed/21320950">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2220 href="http://dx.doi.org/10.1001/archophthalmol.2011.5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13296974">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d4312e2233 class=n-a></a>Munier FL: Classification and management of seeds in retinoblastoma. Ellsworth Lecture Ghent August 24th 2013. <i>Ophthalmic Genet.</i> 2014; <b>35</b>(4): 193–207. <a target=xrefwindow id=d4312e2241 href="http://www.ncbi.nlm.nih.gov/pubmed/25321846">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2244 href="http://dx.doi.org/10.3109/13816810.2014.973045">Publisher Full Text </a> | <a target=xrefwindow id=d4312e2247 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4245997">Free Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d4312e2256 class=n-a></a>Ghassemi F, Shields CL: Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. <i>Arch Ophthalmol.</i> 2012; <b>130</b>(10): 1268–71. <a target=xrefwindow id=d4312e2264 href="http://www.ncbi.nlm.nih.gov/pubmed/23044940">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2267 href="http://dx.doi.org/10.1001/archophthalmol.2012.1983">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d4312e2277 class=n-a></a>Munier FL, Gaillard MC, Balmer A, <i> et al.</i>: Intravitreal chemotherapy for vitreous seeding in retinoblastoma: Recent advances and perspectives. <i>Saudi J Ophthalmol.</i> 2013; <b>27</b>(3): 147–50. <a target=xrefwindow id=d4312e2288 href="http://www.ncbi.nlm.nih.gov/pubmed/24227979">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2291 href="http://dx.doi.org/10.1016/j.sjopt.2013.06.003">Publisher Full Text </a> | <a target=xrefwindow id=d4312e2295 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3770220">Free Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d4312e2304 class=n-a></a>Francis JH, Abramson DH, Ji X, <i> et al.</i>: Risk of Extraocular Extension in Eyes With Retinoblastoma Receiving Intravitreous Chemotherapy. <i>JAMA Ophthalmol.</i> 2017; <b>135</b>(12): 1426–9. <a target=xrefwindow id=d4312e2315 href="http://www.ncbi.nlm.nih.gov/pubmed/29098285">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2318 href="http://dx.doi.org/10.1001/jamaophthalmol.2017.4600">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718347985"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e2327 class=n-a></a>Munier FL, Soliman S, Moulin AP, <i> et al.</i>: Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track. <i>Br J Ophthalmol.</i> 2012; <b>96</b>(8): 1084–7. <a target=xrefwindow id=d4312e2338 href="http://www.ncbi.nlm.nih.gov/pubmed/22368262">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2341 href="http://dx.doi.org/10.1136/bjophthalmol-2011-301016">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718347985">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d4312e2354 class=n-a></a>Kingston JE, Hungerford JL, Madreperla SA, <i> et al.</i>: Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. <i>Arch Ophthalmol.</i> 1996; <b>114</b>(11): 1339–43. <a target=xrefwindow id=d4312e2365 href="http://www.ncbi.nlm.nih.gov/pubmed/8906024">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2368 href="http://dx.doi.org/10.1001/archopht.1996.01100140539004">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726403080"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e2377 class=n-a></a>Mendoza PR, Grossniklaus HE: Therapeutic Options for Retinoblastoma. <i>Cancer Control.</i> 2016; <b>23</b>(2): 99–109. <a target=xrefwindow id=d4312e2385 href="http://www.ncbi.nlm.nih.gov/pubmed/27218786">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2388 href="http://dx.doi.org/10.1177/107327481602300203">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726403080">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d4312e2401 class=n-a></a>Shields CL, Mashayekhi A, Au AK, <i> et al.</i>: The International Classification of Retinoblastoma predicts chemoreduction success. <i>Ophthalmology.</i> 2006; <b>113</b>(12): 2276–80. <a target=xrefwindow id=d4312e2412 href="http://www.ncbi.nlm.nih.gov/pubmed/16996605">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2415 href="http://dx.doi.org/10.1016/j.ophtha.2006.06.018">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d4312e2425 class=n-a></a>Shields CL, Shields JA, Meadows AT: Chemoreduction for retinoblastoma may prevent trilateral retinoblastoma. <i>J Clin Oncol.</i> 2000; <b>18</b>(1): 236–7. <a target=xrefwindow id=d4312e2433 href="http://www.ncbi.nlm.nih.gov/pubmed/10623718">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2436 href="http://dx.doi.org/10.1200/JCO.2000.18.1.236">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d4312e2445 class=n-a></a>Dunkel IJ, Jubran RF, Gururangan S, <i> et al.</i>: Trilateral retinoblastoma: potentially curable with intensive chemotherapy. <i>Pediatr Blood Cancer.</i> 2010; <b>54</b>(3): 384–7. <a target=xrefwindow id=d4312e2456 href="http://www.ncbi.nlm.nih.gov/pubmed/19908299">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2459 href="http://dx.doi.org/10.1002/pbc.22336">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725692111"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e2468 class=n-a></a>Ortiz MV, Dunkel IJ: Retinoblastoma. <i>J Child Neurol.</i> 2016; <b>31</b>(2): 227–36. <a target=xrefwindow id=d4312e2476 href="http://www.ncbi.nlm.nih.gov/pubmed/26023180">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2479 href="http://dx.doi.org/10.1177/0883073815587943">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725692111">F1000 Recommendation</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d4312e2492 class=n-a></a>Shields CL, Mashayekhi A, Sun H, <i> et al.</i>: Iodine 125 plaque radiotherapy as salvage treatment for retinoblastoma recurrence after chemoreduction in 84 tumors. <i>Ophthalmology.</i> 2006; <b>113</b>(11): 2087–92. <a target=xrefwindow id=d4312e2503 href="http://www.ncbi.nlm.nih.gov/pubmed/16949158">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2506 href="http://dx.doi.org/10.1016/j.ophtha.2006.04.032">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d4312e2515 class=n-a></a>Francis JH, Barker CA, Wolden SL, <i> et al.</i>: Salvage/adjuvant brachytherapy after ophthalmic artery chemosurgery for intraocular retinoblastoma. <i>Int J Radiat Oncol Biol Phys.</i> 2013; <b>87</b>(3): 517–23. <a target=xrefwindow id=d4312e2526 href="http://www.ncbi.nlm.nih.gov/pubmed/23953635">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2529 href="http://dx.doi.org/10.1016/j.ijrobp.2013.06.2045">Publisher Full Text </a> | <a target=xrefwindow id=d4312e2533 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4843130">Free Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d4312e2542 class=n-a></a>McLaughlin CC, Wu XC, Jemal A, <i> et al.</i>: Incidence of noncutaneous melanomas in the U.S. <i>Cancer.</i> 2005; <b>103</b>(5): 1000–7. <a target=xrefwindow id=d4312e2553 href="http://www.ncbi.nlm.nih.gov/pubmed/15651058">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2556 href="http://dx.doi.org/10.1002/cncr.20866">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d4312e2566 class=n-a></a>Collaborative Ocular Melanoma Study Group: Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. <i>Arch Ophthalmol</i>. 2001; <b>119</b>(5): 670–6. <a target=xrefwindow id=d4312e2574 href="http://www.ncbi.nlm.nih.gov/pubmed/11346394">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2577 href="http://dx.doi.org/10.1001/archopht.119.5.670">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d4312e2586 class=n-a></a>Singh AD, Topham A: Survival rates with uveal melanoma in the United States: 1973–1997. <i>Ophthalmology.</i> 2003; <b>110</b>(5): 962–5. <a target=xrefwindow id=d4312e2594 href="http://www.ncbi.nlm.nih.gov/pubmed/12750098">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2597 href="http://dx.doi.org/10.1016/S0161-6420(03)00077-0">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d4312e2606 class=n-a></a>Diener-West M, Reynolds SM, Agugliaro DJ, <i> et al.</i>: Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. <i>Arch Ophthalmol.</i> 2005; <b>123</b>(12): 1639–43. <a target=xrefwindow id=d4312e2617 href="http://www.ncbi.nlm.nih.gov/pubmed/16344433">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2620 href="http://dx.doi.org/10.1001/archopht.123.12.1639">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d4312e2629 class=n-a></a>Kujala E, Mäkitie T, Kivelä T: Very long-term prognosis of patients with malignant uveal melanoma. <i>Invest Ophthalmol Vis Sci.</i> 2003; <b>44</b>(11): 4651–9. <a target=xrefwindow id=d4312e2637 href="http://www.ncbi.nlm.nih.gov/pubmed/14578381">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2640 href="http://dx.doi.org/10.1167/iovs.03-0538">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d4312e2649 class=n-a></a>Diener-West M, Earle JD, Fine SL, <i> et al.</i>: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. <i>Arch Ophthalmol.</i> 2001; <b>119</b>(7): 969–82. <a target=xrefwindow id=d4312e2660 href="http://www.ncbi.nlm.nih.gov/pubmed/11448319">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2663 href="http://dx.doi.org/10.1001/archopht.119.7.969">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d4312e2672 class=n-a></a>Kim IK, Lane AM, Gragoudas ES: Survival in patients with presymptomatic diagnosis of metastatic uveal melanoma. <i>Arch Ophthalmol.</i> 2010; <b>128</b>(7): 871–5. <a target=xrefwindow id=d4312e2680 href="http://www.ncbi.nlm.nih.gov/pubmed/20625048">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2683 href="http://dx.doi.org/10.1001/archophthalmol.2010.121">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717953857"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e2693 class=n-a></a>Njauw CN, Kim I, Piris A, <i> et al.</i>: Germline <i>BAP1</i> inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. <i>PLoS One.</i> 2012; <b>7</b>(4): e35295. <a target=xrefwindow id=d4312e2707 href="http://www.ncbi.nlm.nih.gov/pubmed/22545102">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2711 href="http://dx.doi.org/10.1371/journal.pone.0035295">Publisher Full Text </a> | <a target=xrefwindow id=d4312e2714 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3335872">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717953857">F1000 Recommendation</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d4312e2727 class=n-a></a>Collaborative Ocular Melanoma Study Group: Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS report no. 6. <i>Am J Ophthalmol</i>. 1998; <b>125</b>(6): 745–66. <a target=xrefwindow id=d4312e2735 href="http://www.ncbi.nlm.nih.gov/pubmed/9645714">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2738 href="http://dx.doi.org/10.1016/S0002-9394(98)00040-3">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d4312e2747 class=n-a></a>Augsburger JJ, Corrêa ZM, Trichopoulos N: Prognostic implications of cytopathologic classification of melanocytic uveal tumors evaluated by fine-needle aspiration biopsy. <i>Arq Bras Oftalmol.</i> 2013; <b>76</b>(2): 72–9. <a target=xrefwindow id=d4312e2755 href="http://www.ncbi.nlm.nih.gov/pubmed/23828465">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2758 href="http://dx.doi.org/10.1590/S0004-27492013000200004">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d4312e2767 class=n-a></a>Prescher G, Bornfeld N, Becher R: Nonrandom chromosomal abnormalities in primary uveal melanoma. <i>J Natl Cancer Inst.</i> 1990; <b>82</b>(22): 1765–9. <a target=xrefwindow id=d4312e2775 href="http://www.ncbi.nlm.nih.gov/pubmed/2231772">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2778 href="http://dx.doi.org/10.1093/jnci/82.22.1765">Publisher Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726767236"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e2787 class=n-a></a>Helgadottir H, Höiom V: The genetics of uveal melanoma: current insights. <i>Appl Clin Genet.</i> 2016; <b>9</b>: 147–55. <a target=xrefwindow id=d4312e2795 href="http://www.ncbi.nlm.nih.gov/pubmed/27660484">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2798 href="http://dx.doi.org/10.2147/TACG.S69210">Publisher Full Text </a> | <a target=xrefwindow id=d4312e2801 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5019476">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726767236">F1000 Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717961831"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e2814 class=n-a></a>Daniels AB, Lee JE, MacConaill LE, <i> et al.</i>: High throughput mass spectrometry-based mutation profiling of primary uveal melanoma. <i>Invest Ophthalmol Vis Sci.</i> 2012; <b>53</b>(11): 6991–6. <a target=xrefwindow id=d4312e2825 href="http://www.ncbi.nlm.nih.gov/pubmed/22977135">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2828 href="http://dx.doi.org/10.1167/iovs.12-10427">Publisher Full Text </a> | <a target=xrefwindow id=d4312e2832 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3471553">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717961831">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/9576958"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e2846 class=n-a></a>Harbour JW, Onken MD, Roberson ED, <i> et al.</i>: Frequent mutation of <i>BAP1</i> in metastasizing uveal melanomas. <i>Science.</i> 2010; <b>330</b>(6009): 1410–3. <a target=xrefwindow id=d4312e2860 href="http://www.ncbi.nlm.nih.gov/pubmed/21051595">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2864 href="http://dx.doi.org/10.1126/science.1194472">Publisher Full Text </a> | <a target=xrefwindow id=d4312e2867 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3087380">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/9576958">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d4312e2880 class=n-a></a>Chang SH, Worley LA, Onken MD, <i> et al.</i>: Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis. <i>Melanoma Res.</i> 2008; <b>18</b>(3): 191–200. <a target=xrefwindow id=d4312e2891 href="http://www.ncbi.nlm.nih.gov/pubmed/18477893">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2894 href="http://dx.doi.org/10.1097/CMR.0b013e3283005270">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d4312e2903 class=n-a></a>Martin M, Maßhöfer L, Temming P, <i> et al.</i>: Exome sequencing identifies recurrent somatic mutations in <i>EIF1AX</i> and <i>SF3B1</i> in uveal melanoma with disomy 3. <i>Nat Genet.</i> 2013; <b>45</b>(8): 933–6. <a target=xrefwindow id=d4312e2921 href="http://www.ncbi.nlm.nih.gov/pubmed/23793026">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2924 href="http://dx.doi.org/10.1038/ng.2674">Publisher Full Text </a> | <a target=xrefwindow id=d4312e2927 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4307600">Free Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726180822"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e2936 class=n-a></a>Yavuzyigitoglu S, Koopmans AE, Verdijk RM, <i> et al.</i>: Uveal Melanomas with <i>SF3B1</i> Mutations: A Distinct Subclass Associated with Late-Onset Metastases. <i>Ophthalmology.</i> 2016; <b>123</b>(5): 1118–28. <a target=xrefwindow id=d4312e2950 href="http://www.ncbi.nlm.nih.gov/pubmed/26923342">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2954 href="http://dx.doi.org/10.1016/j.ophtha.2016.01.023">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726180822">F1000 Recommendation</a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d4312e2967 class=n-a></a>Field MG, Harbour JW: Recent developments in prognostic and predictive testing in uveal melanoma. <i>Curr Opin Ophthalmol.</i> 2014; <b>25</b>(3): 234–9. <a target=xrefwindow id=d4312e2975 href="http://www.ncbi.nlm.nih.gov/pubmed/24713608">PubMed Abstract </a> | <a target=xrefwindow id=d4312e2978 href="http://dx.doi.org/10.1097/ICU.0000000000000051">Publisher Full Text </a> | <a target=xrefwindow id=d4312e2981 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4467564">Free Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d4312e2990 class=n-a></a>Onken MD, Worley LA, Ehlers JP, <i> et al.</i>: Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. <i>Cancer Res.</i> 2004; <b>64</b>(20): 7205–9. <a target=xrefwindow id=d4312e3001 href="http://www.ncbi.nlm.nih.gov/pubmed/15492234">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3004 href="http://dx.doi.org/10.1158/0008-5472.CAN-04-1750">Publisher Full Text </a> | <a target=xrefwindow id=d4312e3008 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5407684">Free Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d4312e3018 class=n-a></a>Damato B, Dopierala J, Klaasen A, <i> et al.</i>: Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death. <i>Invest Ophthalmol Vis Sci.</i> 2009; <b>50</b>(7): 3048–55. <a target=xrefwindow id=d4312e3029 href="http://www.ncbi.nlm.nih.gov/pubmed/19182252">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3032 href="http://dx.doi.org/10.1167/iovs.08-3165">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d4312e3041 class=n-a></a>Harbour JW, Chen R: The DecisionDx-UM Gene Expression Profile Test Provides Risk Stratification and Individualized Patient Care in Uveal Melanoma. <i>PLoS Curr.</i> 2013; <b>5</b>: pii: ecurrents.eogt.af8ba80fc776c8f1ce8f5dc485d4a618. <a target=xrefwindow id=d4312e3049 href="http://www.ncbi.nlm.nih.gov/pubmed/23591547">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3052 href="http://dx.doi.org/10.1371/currents.eogt.af8ba80fc776c8f1ce8f5dc485d4a618">Publisher Full Text </a> | <a target=xrefwindow id=d4312e3055 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3625622">Free Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726319449"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e3064 class=n-a></a>Decatur CL, Ong E, Garg N, <i> et al.</i>: Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes. <i>JAMA Ophthalmol.</i> 2016; <b>134</b>(7): 728–33. <a target=xrefwindow id=d4312e3075 href="http://www.ncbi.nlm.nih.gov/pubmed/27123562">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3078 href="http://dx.doi.org/10.1001/jamaophthalmol.2016.0903">Publisher Full Text </a> | <a target=xrefwindow id=d4312e3082 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4966162">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726319449">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727609150"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e3095 class=n-a></a>Shields CL, Say EAT, Hasanreisoglu M, <i> et al.</i>: Personalized Prognosis of Uveal Melanoma Based on Cytogenetic Profile in 1059 Patients over an 8-Year Period: The 2017 Harry S. Gradle Lecture. <i>Ophthalmology.</i> 2017; <b>124</b>(10): 1523–31. <a target=xrefwindow id=d4312e3106 href="http://www.ncbi.nlm.nih.gov/pubmed/28495150">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3109 href="http://dx.doi.org/10.1016/j.ophtha.2017.04.003">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727609150">F1000 Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726191530"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e3122 class=n-a></a>Field MG, Decatur CL, Kurtenbach S, <i> et al.</i>: PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma. <i>Clin Cancer Res.</i> 2016; <b>22</b>(5): 1234–42. <a target=xrefwindow id=d4312e3133 href="http://www.ncbi.nlm.nih.gov/pubmed/26933176">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3136 href="http://dx.doi.org/10.1158/1078-0432.CCR-15-2071">Publisher Full Text </a> | <a target=xrefwindow id=d4312e3140 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4780366">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726191530">F1000 Recommendation</a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726605946"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e3153 class=n-a></a>Field MG, Durante MA, Decatur CL, <i> et al.</i>: Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas. <i>Oncotarget.</i> 2016; <b>7</b>(37): 59209–19. <a target=xrefwindow id=d4312e3164 href="http://www.ncbi.nlm.nih.gov/pubmed/27486988">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3167 href="http://dx.doi.org/10.18632/oncotarget.10962">Publisher Full Text </a> | <a target=xrefwindow id=d4312e3171 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5312306">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726605946">F1000 Recommendation</a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727461584"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e3185 class=n-a></a>Reichstein D: New concepts in the molecular understanding of uveal melanoma. <i>Curr Opin Ophthalmol.</i> 2017; <b>28</b>(3): 219–27. <a target=xrefwindow id=d4312e3193 href="http://www.ncbi.nlm.nih.gov/pubmed/28257297">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3196 href="http://dx.doi.org/10.1097/ICU.0000000000000366">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727461584">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727557466"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e3209 class=n-a></a>Gezgin G, Luk SJ, Cao J, <i> et al.</i>: PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma. <i>JAMA Ophthalmol.</i> 2017; <b>135</b>(6): 541–9. <a target=xrefwindow id=d4312e3220 href="http://www.ncbi.nlm.nih.gov/pubmed/28448663">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3223 href="http://dx.doi.org/10.1001/jamaophthalmol.2017.0729">Publisher Full Text </a> | <a target=xrefwindow id=d4312e3227 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5509351">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727557466">F1000 Recommendation</a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d4312e3240 class=n-a></a>Kim RS, Chevez-Barrios P, Bretana ME, <i> et al.</i>: Histopathologic Analysis of Transvitreal Fine Needle Aspiration Biopsy Needle Tracts for Uveal Melanoma. <i>Am J Ophthalmol.</i> 2017; <b>174</b>: 9–16. <a target=xrefwindow id=d4312e3251 href="http://www.ncbi.nlm.nih.gov/pubmed/27818205">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3254 href="http://dx.doi.org/10.1016/j.ajo.2016.10.019">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d4312e3263 class=n-a></a>Shields CL, Ganguly A, Materin MA, <i> et al.</i>: Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases. <i>Trans Am Ophthalmol Soc.</i> 2007; <b>105</b>: 43–52; discussion 52–3. <a target=xrefwindow id=d4312e3274 href="http://www.ncbi.nlm.nih.gov/pubmed/18427593">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3277 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2258107">Free Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718492027"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e3286 class=n-a></a>Chang MY, McCannel TA: Comparison of uveal melanoma cytopathologic sample retrieval in trans-scleral versus vitrectomy-assisted transvitreal fine needle aspiration biopsy. <i>Br J Ophthalmol.</i> 2014; <b>98</b>(12): 1654–8. <a target=xrefwindow id=d4312e3294 href="http://www.ncbi.nlm.nih.gov/pubmed/24997179">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3297 href="http://dx.doi.org/10.1136/bjophthalmol-2014-305181">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718492027">F1000 Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725929265"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e3310 class=n-a></a>Sellam A, Desjardins L, Barnhill R, <i> et al.</i>: Fine Needle Aspiration Biopsy in Uveal Melanoma: Technique, Complications, and Outcomes. <i>Am J Ophthalmol.</i> 2016; <b>162</b>: 28–34.e1. <a target=xrefwindow id=d4312e3321 href="http://www.ncbi.nlm.nih.gov/pubmed/26556006">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3324 href="http://dx.doi.org/10.1016/j.ajo.2015.11.005">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725929265">F1000 Recommendation</a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725690983"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e3338 class=n-a></a>Singh AD, Medina CA, Singh N, <i> et al.</i>: Fine-needle aspiration biopsy of uveal melanoma: outcomes and complications. <i>Br J Ophthalmol.</i> 2016; <b>100</b>(4): 456–62. <a target=xrefwindow id=d4312e3349 href="http://www.ncbi.nlm.nih.gov/pubmed/26231747">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3352 href="http://dx.doi.org/10.1136/bjophthalmol-2015-306921">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725690983">F1000 Recommendation</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d4312e3365 class=n-a></a>Correa ZM, Augsburger JJ: Sufficiency of FNAB aspirates of posterior uveal melanoma for cytologic versus GEP classification in 159 patients, and relative prognostic significance of these classifications. <i>Graefes Arch Clin Exp Ophthalmol.</i> 2014; <b>252</b>(1): 131–5. <a target=xrefwindow id=d4312e3373 href="http://www.ncbi.nlm.nih.gov/pubmed/24270974">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3376 href="http://dx.doi.org/10.1007/s00417-013-2515-0">Publisher Full Text </a> | <a target=xrefwindow id=d4312e3379 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3889697">Free Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d4312e3388 class=n-a></a>Jampol LM, Moy CS, Murray TG, <i> et al.</i>: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. <i>Ophthalmology.</i> 2002; <b>109</b>(12): 2197–206. <a target=xrefwindow id=d4312e3399 href="http://www.ncbi.nlm.nih.gov/pubmed/12466159">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3402 href="http://dx.doi.org/10.1016/S0161-6420(02)01277-0">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d4312e3411 class=n-a></a>Nag S, Quivey JM, Earle JD, <i> et al.</i>: The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas. <i>Int J Radiat Oncol Biol Phys.</i> 2003; <b>56</b>(2): 544–55. <a target=xrefwindow id=d4312e3422 href="http://www.ncbi.nlm.nih.gov/pubmed/12738332">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3425 href="http://dx.doi.org/10.1016/S0360-3016(03)00006-3">Publisher Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d4312e3434 class=n-a></a>Collaborative Ocular Melanoma Study Group: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. <i>Arch Ophthalmol.</i> 2006; <b>124</b>(12): 1684–93. <a target=xrefwindow id=d4312e3442 href="http://www.ncbi.nlm.nih.gov/pubmed/17159027">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3445 href="http://dx.doi.org/10.1001/archopht.124.12.1684">Publisher Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725881225"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e3454 class=n-a></a>Ophthalmic Oncology Task Force: Local Recurrence Significantly Increases the Risk of Metastatic Uveal Melanoma. <i>Ophthalmology.</i> 2016; <b>123</b>(1): 86–91. <a target=xrefwindow id=d4312e3462 href="http://www.ncbi.nlm.nih.gov/pubmed/26505803">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3465 href="http://dx.doi.org/10.1016/j.ophtha.2015.09.014">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725881225">F1000 Recommendation</a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d4312e3479 class=n-a></a>Harbour JW, Char DH, Kroll S, <i> et al.</i>: Metastatic risk for distinct patterns of postirradiation local recurrence of posterior uveal melanoma. <i>Ophthalmology.</i> 1997; <b>104</b>(11): 1785–92; discussion 1792–3. <a target=xrefwindow id=d4312e3490 href="http://www.ncbi.nlm.nih.gov/pubmed/9373108">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3493 href="http://dx.doi.org/10.1016/S0161-6420(97)30025-6">Publisher Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d4312e3502 class=n-a></a>Berry JL, Dandapani SV, Stevanovic M, <i> et al.</i>: Outcomes of choroidal melanomas treated with eye physics: a 20-year review. <i>JAMA Ophthalmol.</i> 2013; <b>131</b>(11): 1435–42. <a target=xrefwindow id=d4312e3513 href="http://www.ncbi.nlm.nih.gov/pubmed/24008431">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3516 href="http://dx.doi.org/10.1001/jamaophthalmol.2013.4422">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d4312e3525 class=n-a></a>Tann AW, Teh BS, Scarboro SB, <i> et al.</i>: Early outcomes of uveal melanoma treated with intraoperative ultrasound guided brachytherapy using custom built plaques. <i>Pract Radiat Oncol.</i> 2017; <b>7</b>(4): e275–e282. <a target=xrefwindow id=d4312e3536 href="http://www.ncbi.nlm.nih.gov/pubmed/28377140">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3539 href="http://dx.doi.org/10.1016/j.prro.2017.01.002">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d4312e3548 class=n-a></a>Astrahan MA, Luxton G, Pu Q, <i> et al.</i>: Conformal episcleral plaque therapy. <i>Int J Radiat Oncol Biol Phys.</i> 1997; <b>39</b>(2): 505–19. <a target=xrefwindow id=d4312e3559 href="http://www.ncbi.nlm.nih.gov/pubmed/9308957">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3562 href="http://dx.doi.org/10.1016/S0360-3016(97)00118-1">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d4312e3571 class=n-a></a>Astrahan MA, Luxton G, Jozsef G, <i> et al.</i>: Optimization of <sup>125</sup>I ophthalmic plaque brachytherapy. <i>Med Phys.</i> 1990; <b>17</b>(6): 1053–7. <a target=xrefwindow id=d4312e3585 href="http://www.ncbi.nlm.nih.gov/pubmed/2280735">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3589 href="http://dx.doi.org/10.1118/1.596585">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d4312e3598 class=n-a></a>Harbour JW, Murray TG, Byrne SF, <i> et al.</i>: Intraoperative echographic localization of iodine 125 episcleral radioactive plaques for posterior uveal melanoma. <i>Retina.</i> 1996; <b>16</b>(2): 129–34. <a target=xrefwindow id=d4312e3609 href="http://www.ncbi.nlm.nih.gov/pubmed/8724957">PubMed Abstract </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d4312e3619 class=n-a></a>Tabandeh H, Chaudhry NA, Murray TG, <i> et al.</i>: Intraoperative echographic localization of iodine-125 episcleral plaque for brachytherapy of choroidal melanoma. <i>Am J Ophthalmol.</i> 2000; <b>129</b>(2): 199–204. <a target=xrefwindow id=d4312e3630 href="http://www.ncbi.nlm.nih.gov/pubmed/10682973">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3633 href="http://dx.doi.org/10.1016/S0002-9394(99)00315-3">Publisher Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d4312e3642 class=n-a></a>Finger PT: Intraoperative echographic localization of iodine-125 episcleral plaque for brachytherapy of choroidal melanoma. <i>Am J Ophthalmol.</i> 2000; <b>130</b>(4): 539–40. <a target=xrefwindow id=d4312e3650 href="http://www.ncbi.nlm.nih.gov/pubmed/11183561">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3653 href="http://dx.doi.org/10.1016/S0002-9394(00)00549-3">Publisher Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726696899"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e3662 class=n-a></a>Aziz HA, Al Zahrani YA, Bena J, <i> et al.</i>: Episcleral brachytherapy of uveal melanoma: role of intraoperative echographic confirmation. <i>Br J Ophthalmol.</i> 2017; <b>101</b>(6): 747–51. <a target=xrefwindow id=d4312e3673 href="http://www.ncbi.nlm.nih.gov/pubmed/27574179">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3676 href="http://dx.doi.org/10.1136/bjophthalmol-2016-309153">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726696899">F1000 Recommendation</a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d4312e3689 class=n-a></a>Astrahan MA, Luxton G, Jozsef G, <i> et al.</i>: An interactive treatment planning system for ophthalmic plaque radiotherapy. <i>Int J Radiat Oncol Biol Phys.</i> 1990; <b>18</b>(3): 679–87. <a target=xrefwindow id=d4312e3700 href="http://www.ncbi.nlm.nih.gov/pubmed/2318702">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3703 href="http://dx.doi.org/10.1016/0360-3016(90)90077-W">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d4312e3712 class=n-a></a>Wang Z, Nabhan M, Schild SE, <i> et al.</i>: Charged particle radiation therapy for uveal melanoma: a systematic review and meta-analysis. <i>Int J Radiat Oncol Biol Phys.</i> 2013; <b>86</b>(1): 18–26. <a target=xrefwindow id=d4312e3723 href="http://www.ncbi.nlm.nih.gov/pubmed/23040219">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3726 href="http://dx.doi.org/10.1016/j.ijrobp.2012.08.026">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/730184944"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e3735 class=n-a></a>Mishra KK, Daftari IK: Proton therapy for the management of uveal melanoma and other ocular tumors. <i>Chin Clin Oncol.</i> 2016; <b>5</b>(4): 50. <a target=xrefwindow id=d4312e3743 href="http://www.ncbi.nlm.nih.gov/pubmed/27558251">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3746 href="http://dx.doi.org/10.21037/cco.2016.07.06">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/730184944">F1000 Recommendation</a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a name=d4312e3760 class=n-a></a>Melia BM, Abramson DH, Albert DM, <i> et al.</i>: Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. <i>Ophthalmology.</i> 2001; <b>108</b>(2): 348–66. <a target=xrefwindow id=d4312e3771 href="http://www.ncbi.nlm.nih.gov/pubmed/11158813">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3774 href="http://dx.doi.org/10.1016/S0161-6420(00)00526-1">Publisher Full Text </a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725957649"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e3783 class=n-a></a>Corrêa ZM, Augsburger JJ: Independent Prognostic Significance of Gene Expression Profile Class and Largest Basal Diameter of Posterior Uveal Melanomas. <i>Am J Ophthalmol.</i> 2016; <b>162</b>: 20–27.e1. <a target=xrefwindow id=d4312e3791 href="http://www.ncbi.nlm.nih.gov/pubmed/26596399">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3794 href="http://dx.doi.org/10.1016/j.ajo.2015.11.019">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725957649">F1000 Recommendation</a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726319447"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e3807 class=n-a></a>Walter SD, Chao DL, Feuer W, <i> et al.</i>: Prognostic Implications of Tumor Diameter in Association With Gene Expression Profile for Uveal Melanoma. <i>JAMA Ophthalmol.</i> 2016; <b>134</b>(7): 734–40. <a target=xrefwindow id=d4312e3818 href="http://www.ncbi.nlm.nih.gov/pubmed/27123792">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3821 href="http://dx.doi.org/10.1001/jamaophthalmol.2016.0913">Publisher Full Text </a> | <a target=xrefwindow id=d4312e3825 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4966166">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726319447">F1000 Recommendation</a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d4312e3838 class=n-a></a>Schefler A, Berry D, Seider M, <i> et al.</i>: Ocular Oncology Study Consortium Report 3: Baseline clinical features and relationship to GEP Class. <i>Association for Research in Vision and Ophthalmology.</i> Baltimore, MD. 2017.</span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d4312e3853 class=n-a></a>Chew AL, Spilsbury K, Isaacs TW: Survival from uveal melanoma in Western Australia 1981–2005. <i>Clin Exp Ophthalmol.</i> 2015; <b>43</b>(5): 422–8. <a target=xrefwindow id=d4312e3861 href="http://www.ncbi.nlm.nih.gov/pubmed/25556534">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3864 href="http://dx.doi.org/10.1111/ceo.12490">Publisher Full Text </a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d4312e3873 class=n-a></a>Kaiserman I, Anteby I, Chowers I, <i> et al.</i>: Post-brachytherapy initial tumour regression rate correlates with metastatic spread in posterior uveal melanoma. <i>Br J Ophthalmol.</i> 2004; <b>88</b>(7): 892–5. <a target=xrefwindow id=d4312e3884 href="http://www.ncbi.nlm.nih.gov/pubmed/15205232">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3887 href="http://dx.doi.org/10.1136/bjo.2003.036285">Publisher Full Text </a> | <a target=xrefwindow id=d4312e3891 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1772205">Free Full Text </a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d4312e3901 class=n-a></a>Shields CL, Bianciotto C, Rudich D, <i> et al.</i>: Regression of uveal melanoma after plaque radiotherapy and thermotherapy based on chromosome 3 status. <i>Retina.</i> 2008; <b>28</b>(9): 1289–95. <a target=xrefwindow id=d4312e3912 href="http://www.ncbi.nlm.nih.gov/pubmed/18628721">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3915 href="http://dx.doi.org/10.1097/IAE.0b013e31817f7b3e">Publisher Full Text </a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726174282"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d4312e3924 class=n-a></a>Gupta K, McCannel CA, Kamrava M, <i> et al.</i>: Tumor-height regression rate after brachytherapy between choroidal melanoma gene expression profile classes: effect of controlling for tumor height. <i>Graefes Arch Clin Exp Ophthalmol.</i> 2016; <b>254</b>(7): 1371–8. <a target=xrefwindow id=d4312e3935 href="http://www.ncbi.nlm.nih.gov/pubmed/26907932">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3938 href="http://dx.doi.org/10.1007/s00417-016-3305-2">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726174282">F1000 Recommendation</a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d4312e3951 class=n-a></a>Corrêa ZM, Augsburger JJ: Relationship between rate of posterior uveal melanoma flattening following plaque radiotherapy and gene expression profile class of tumor cells. <i>Invest Ophthalmol Vis Sci.</i> 2014; <b>55</b>(1): 556–9. <a target=xrefwindow id=d4312e3959 href="http://www.ncbi.nlm.nih.gov/pubmed/24408979">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3962 href="http://dx.doi.org/10.1167/iovs.13-13381">Publisher Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d4312e3971 class=n-a></a>Rao RC, Khan M, Badiyan SN, <i> et al.</i>: Gene expression profiling and regression rate of irradiated uveal melanomas. <i>Ophthalmic Surg Lasers Imaging Retina.</i> 2015; <b>46</b>(3): 333–7. <a target=xrefwindow id=d4312e3982 href="http://www.ncbi.nlm.nih.gov/pubmed/25856819">PubMed Abstract </a> | <a target=xrefwindow id=d4312e3985 href="http://dx.doi.org/10.3928/23258160-20150323-06">Publisher Full Text </a> | <a target=xrefwindow id=d4312e3989 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4398963">Free Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d4312e3998 class=n-a></a>Mruthyunjaya P, Seider MI, Stinnett S, <i> et al.</i>: Association between Tumor Regression Rate and Gene Expression Profile after Iodine 125 Plaque Radiotherapy for Uveal Melanoma. <i>Ophthalmology.</i> 2017; <b>124</b>(10): 1532–9. <a target=xrefwindow id=d4312e4009 href="http://www.ncbi.nlm.nih.gov/pubmed/28549517">PubMed Abstract </a> | <a target=xrefwindow id=d4312e4012 href="http://dx.doi.org/10.1016/j.ophtha.2017.04.013">Publisher Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a name=d4312e4021 class=n-a></a>Landreville S, Agapova OA, Matatall KA, <i> et al.</i>: Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. <i>Clin Cancer Res.</i> 2012; <b>18</b>(2): 408–16. <a target=xrefwindow id=d4312e4032 href="http://www.ncbi.nlm.nih.gov/pubmed/22038994">PubMed Abstract </a> | <a target=xrefwindow id=d4312e4035 href="http://dx.doi.org/10.1158/1078-0432.CCR-11-0946">Publisher Full Text </a> | <a target=xrefwindow id=d4312e4039 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3261307">Free Full Text </a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a name=d4312e4049 class=n-a></a>Chen X, Wu Q, Tan L, <i> et al.</i>: Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. <i>Oncogene.</i> 2014; <b>33</b>(39): 4724–34. <a target=xrefwindow id=d4312e4060 href="http://www.ncbi.nlm.nih.gov/pubmed/24141786">PubMed Abstract </a> | <a target=xrefwindow id=d4312e4063 href="http://dx.doi.org/10.1038/onc.2013.418">Publisher Full Text </a> | <a target=xrefwindow id=d4312e4067 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4524511">Free Full Text </a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a name=d4312e4076 class=n-a></a>Nowis D, Makowski M, Stoklosa T, <i> et al.</i>: Direct tumor damage mechanisms of photodynamic therapy. <i>Acta Biochim Pol.</i> 2005; <b>52</b>(2): 339–52. <a target=xrefwindow id=d4312e4087 href="http://www.ncbi.nlm.nih.gov/pubmed/15990919">PubMed Abstract </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 18 Apr 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-476&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-476&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Retina Consultants of Houston, Houston, TX, 77030, USA<br/> <sup>2</sup> Blanton Eye Institute, Houston Methodist Hospital, Houston, TX, 77030, USA<br/> <sup>3</sup> McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, 77030, USA<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-476/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 18 Apr 2018, 7:476 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.11941.1">https://doi.org/10.12688/f1000research.11941.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2018 Schefler AC and Kim RS. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=12907 data-id=11941 data-downloads="" data-views="" data-scholar="10.12688/f1000research.11941.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-476/v1/pdf?article_uuid=25b3bcb9-73e7-4de1-899f-a51009853953" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.11941.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Schefler AC and Kim RS. Recent advancements in the management of retinoblastoma and uveal melanoma [version 1; peer review: 2 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):476 (<a href="https://doi.org/10.12688/f1000research.11941.1" target=_blank>https://doi.org/10.12688/f1000research.11941.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=11941 id=mobile-track-article-signin-11941 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/11941?target=/articles/7-476"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=12907 /> <input name=articleId type=hidden value=11941 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Zelia Correa</strong>, Department of Ophthalmology, University of Cincinnati, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Richard Carvajal</strong>, Division of Hematology/Oncology, Columbia University Medical Center, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> Aura Biosciences – Clinical Advisor ICONIC Therapeutics – Consulting Castle Biosciences – Consulting (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 18 Apr 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-476&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-476&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=33421-32996></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=33423-32997></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-476/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>18 Apr 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Zelia Correa</strong>, Department of Ophthalmology, University of Cincinnati, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Richard Carvajal</strong>, Division of Hematology/Oncology, Columbia University Medical Center, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> Aura Biosciences – Clinical Advisor ICONIC Therapeutics – Consulting Castle Biosciences – Consulting </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-476&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-476/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advancements in the management of...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-476/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-476/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-476/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Schefler AC and Kim RS');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-476/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-476",
            templates : {
                twitter : "Recent advancements in the management of retinoblastoma and uveal.... Schefler AC and Kim RS, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-476/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advancements in the management of retinoblastoma and uveal melanoma", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advancements in the management of retinoblastoma and uveal melanoma", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/11941/12907")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "12907");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "32996": 0,
                           "32997": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "411cc56e-cef4-4937-a004-79c5f6b65fcc";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-476.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-476.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-476.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-476.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-476.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>